<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Enzyme replacement and substrate reduction therapy for Gaucher disease - Shemesh, E - 2015 | Cochrane Library</title> <meta content="Enzyme replacement and substrate reduction therapy for Gaucher disease - Shemesh, E - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010324.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Enzyme replacement and substrate reduction therapy for Gaucher disease - Shemesh, E - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010324.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010324.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Enzyme replacement and substrate reduction therapy for Gaucher disease" name="citation_title"/> <meta content="Elad Shemesh" name="citation_author"/> <meta content="Israel Defense Forces Medical Corps" name="citation_author_institution"/> <meta content="elad234@gmail.com" name="citation_author_email"/> <meta content="Laura Deroma" name="citation_author"/> <meta content='University Hospital "Santa Maria della Misericordia"' name="citation_author_institution"/> <meta content="Bruno Bembi" name="citation_author"/> <meta content='University Hospital "Santa Maria della Misericordia"' name="citation_author_institution"/> <meta content="Patrick Deegan" name="citation_author"/> <meta content="University of Cambridge and Lysosomal Disorders Unit" name="citation_author_institution"/> <meta content="Carla Hollak" name="citation_author"/> <meta content="Academic Medical Center" name="citation_author_institution"/> <meta content="Neal J Weinreb" name="citation_author"/> <meta content="Timothy M Cox" name="citation_author"/> <meta content="Addenbrooke's Hospital (Box 157)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD010324.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/03/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010324.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010324.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010324.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="1‐Deoxynojirimycin [adverse effects, analogs &amp; derivatives]; Enzyme Inhibitors [adverse effects]; Enzyme Replacement Therapy [*methods]; Gaucher Disease [blood, *drug therapy]; Glucosylceramidase [therapeutic use]; Hemoglobin A [metabolism]; Hepatomegaly [drug therapy]; Platelet Count; Randomized Controlled Trials as Topic; Splenomegaly [drug therapy]; Substrate Specificity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010324.pub2&amp;doi=10.1002/14651858.CD010324.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010324\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010324\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010324.pub2",title:"Enzyme replacement and substrate reduction therapy for Gaucher disease",firstPublishedDate:"Mar 27, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010324.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010324.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010324.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010324.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010324.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010324.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010324.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010324.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010324.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010324.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5369 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010324.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-sec-0026"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-sec-0027"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/appendices#CD010324-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/table_n/CD010324StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/table_n/CD010324StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Enzyme replacement and substrate reduction therapy for Gaucher disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Elad Shemesh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0003">Laura Deroma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0004">Bruno Bembi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0005">Patrick Deegan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0006">Carla Hollak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0007">Neal J Weinreb</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information#CD010324-cr-0008">Timothy M Cox</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information/en#CD010324-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 March 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010324.pub2">https://doi.org/10.1002/14651858.CD010324.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010324-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010324-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010324-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010324-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010324-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010324-abs-0001" lang="en"> <section id="CD010324-sec-0001"> <h3 class="title" id="CD010324-sec-0001">Background</h3> <p>Gaucher disease, a rare disorder, is caused by inherited deficiency of the enzyme glucocerebrosidase. It is unique among the ultra‐orphan disorders in that four treatments are currently approved by various regulatory authorities for use in routine clinical practice. Hitherto, because of the relatively few people affected worldwide, many of whom started therapy during a prolonged period when there were essentially no alternatives to imiglucerase, these treatments have not been systematically evaluated in studies such as randomized controlled trials now considered necessary to generate the highest level of clinical evidence. </p> </section> <section id="CD010324-sec-0002"> <h3 class="title" id="CD010324-sec-0002">Objectives</h3> <p>To summarize all available randomized controlled study data on the efficacy and safety of enzyme replacement therapies and substrate reduction therapy for treating Gaucher disease. </p> </section> <section id="CD010324-sec-0003"> <h3 class="title" id="CD010324-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register. Additional searches were conducted on ClinicalTrials.gov for any ongoing studies with potential interim results, and through PubMed. We also searched the reference lists of relevant articles and reviews. </p> <p>Date of last search: 07 August 2014.</p> </section> <section id="CD010324-sec-0004"> <h3 class="title" id="CD010324-sec-0004">Selection criteria</h3> <p>All randomized and quasi‐randomized controlled studies (including open‐label studies and cross‐over studies) assessing enzyme replacement therapy or substrate reduction therapy, or both, in all types of Gaucher disease were included. </p> </section> <section id="CD010324-sec-0005"> <h3 class="title" id="CD010324-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed the risk of bias in the included studies, and extracted relevant data. </p> </section> <section id="CD010324-sec-0006"> <h3 class="title" id="CD010324-sec-0006">Main results</h3> <p>Of the 488 studies retrieved by the electronic searches, eight met the inclusion criteria and were analysed (300 participants). Response parameters were restricted to haemoglobin concentration, platelet count, spleen and liver volume and serum biomarkers (chitotriosidase and CCL18). Only one publication reported a 'low risk of bias' score in all parameters assessed, and all studies included were randomized. </p> <p>Four studies reported the responses to enzyme replacement therapy of previously untreated individuals with type 1 Gaucher disease. Two studies investigated maintenance enzyme replacement therapy in people with stable type 1 Gaucher disease previously treated for at least two years. One study compared substrate reduction therapy, enzyme replacement therapy and a combination thereof as maintenance therapy in people with type 1 Gaucher disease previously treated with enzyme replacement therapy. One study examined substrate reduction therapy in people with chronic neuronopathic (type 3) Gaucher disease who continued to receive enzyme replacement therapy. </p> <p>Treatment‐naïve participants had similar increases in haemoglobin when comparing those receiving imiglucerase or alglucerase at 60 units/kg, imiglucerase or velaglucerase alfa at 60 U/kg, taliglucerase alfa at 30 units/kg or 60 units/kg, and velaglucerase alfa at 45 units/g or 60 units/kg. For platelet count response in participants with intact spleens, a benefit for imiglucerase over velaglucerase alfa at 60 units/kg was observed, mean difference ‐79.87 (95% confidence interval ‐137.57 to ‐22.17). There were no other significant differences in platelet count response when comparing different doses of velaglucerase alfa and of taliglucerase alfa, and when comparing imiglucerase to alglucerase. Spleen and liver volume reductions were not significantly different in any enzyme replacement therapy product or dose comparison study. Although a dose effect on serum biomarkers was not seen after nine months, a significantly greater reduction with higher dose was reported after 12 months in the velaglucerase study, mean difference 16.70 (95% confidence intervaI 1.51 to 31.89). In the two enzyme replacement therapy maintenance studies comparing infusions every two weeks and every four weeks, there were no significant differences in haemoglobin concentration, platelet count, and spleen and liver volumes over a 6 to 12 month period when participants were treated with the same cumulative dose. </p> <p>A total of 25 serious adverse events were reported, nearly all deemed unrelated to treatment. </p> <p>There are, as yet, no randomized trials of substrate reduction therapy in treatment‐naïve patients that can be evaluated. Miglustat monotherapy appeared as effective as continued enzyme replacement therapy for maintenance of hematological, organ and biomarker responses in people with type 1 Gaucher disease previously treated with imiglucerase for at least two years. In those with neuronopathic Gaucher disease, no significant improvements in haemoglobin concentration, platelet count or organ volumes occurred when enzyme replacement therapy was augmented with miglustat. </p> <p>One randomized controlled study assessing substrate reduction therapy was published immediately prior to producing the final version of this review, and this, along with a further ongoing study (expected to be published in the near future), will be assessed for eligibility in a future update of the review. </p> </section> <section id="CD010324-sec-0007"> <h3 class="title" id="CD010324-sec-0007">Authors' conclusions</h3> <p>The results reflect the limitations of analysing evidence restricted to prospective randomized controlled trials, especially when dealing with chronic rare diseases. This analysis suggests that, during the first year of treatment, different recombinant glucocerebrosidases are bio‐similar and non‐inferior in safety and efficacy for surrogate biological response parameters. Enzyme replacement therapy given at 30 to 45 units/kg body weight every two to four weeks was generally as effective as the 60 unit/kg dose for the assessed clinical outcomes. The analysis emphasise the need to determine whether it is realistic to carry out multi‐decade prospective clinical trials for rare diseases such as type 1 Gaucher disease. With large treatment effects on the classical manifestations of the disorder, therapeutic investigations in Gaucher disease mandate innovative trial designs and methodology to secure decisive data concerning long‐term efficacy and safety – with the realization that knowledge about disease‐modifying actions that are sustained are of crucial importance to people with this chronic condition. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010324-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010324-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010324-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010324-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010324-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010324-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010324-abs-0002" lang="en"> <h3>Treatment options for Gaucher disease</h3> <p>Gaucher disease, a rare disorder, is caused by inherited deficiency of the enzyme glucocerebrosidase. This defect leads to the build‐up of a fatty material called glucocerebroside in various cells in the body. Untreated individuals may suffer from anaemia, a decrease in platelet counts, massive enlargement of the liver and spleen, and damage to the bones. Two different types of treatment are available: the intravenous supplementation of the deficient protein glucocerebrosidase (enzyme replacement therapy), or the oral administration of a drug that slows down the production of the fatty material that it normally breaks down (substrate reduction therapy). </p> <p>Although there are many published studies about treatment of Gaucher disease, those that are based on randomized controlled clinical studies are considered to provide the strongest evidence. Eight such studies (300 participants) were identified by systematically reviewing the medical literature. Potential risks of bias in the methods employed in the original studies and in the data reported were assessed; only one study scored 'low' in all bias domains. Six evaluated the possible beneficial effects on the disease by enzyme replacement therapy using different products, doses or frequencies of administration; two studies examined the effects of substrate reduction therapy. Owing to different study methods and data formats, the original results could not be pooled or combined in order to obtain summary measures of efficacy. Our analysis, despite being limited by the small number of studies, suggests that, at least during the first year of treatment, different enzyme replacement therapy drugs appear to have a similar safety profile and all improve some of the most obvious manifestations of the disease. </p> <p>One randomized controlled study assessing substrate reduction therapy was published immediately prior to producing the final version of this review, and this, along with a further ongoing study (expected to be published in the near future), will be assessed for eligibility in a future update of the review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010324-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010324-sec-0097"></div> <h3 class="title" id="CD010324-sec-0098">Implications for practice</h3> <section id="CD010324-sec-0098"> <p>The limitations of the <i>evidence summarized by this review</i> have been discussed and should also be considered in making decisions in clinical practice. </p> <p>With the recent regulatory approval of taliglucerase alfa in the USA and Israel, and with approval likely to be granted in other jurisdictions in the near future, practitioners caring for people with Gaucher disease who need treatment must choose between four agents: three recombinant glucocerebrosidase glycoproteins with minor differences in primary amino acid sequence and greater differences in carbohydrate structure (imiglucerase, velaglucerase alfa, taliglucerase alfa); and the small molecule, the oral iminosugar, miglustat. The evidence from the small number of included studies provides the clinician with little to no decisive help. </p> <p>There is no randomized controlled study supporting the use of miglustat as a primary intervention for treatment‐naïve patients and this agent is not authorized as a first‐line agent by either the Food and Drug Administration (FDA) or European Medicines Agency (EMA). Two studies (with specific reference only to non‐neurological Gaucher disease manifestations) show that miglustat might be considered as a maintenance‐phase substitute for enzyme replacement therapy in individuals with good disease control, but the relatively short duration of the studies suggests that if individuals are switched from enzyme replacement therapy to miglustat (because of venous access problems or for cost containment), they should be carefully monitored over several years for evidence of disease progression (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). The studies additionally confirmed the significant burden of side effects (gastrointestinal and neurological) identified in the initial non‐randomized studies and repeatedly observed in routine clinical use. The current indication for miglustat use in those unable to tolerate, or unwilling to accept, intravenous ERT is based on a lack of evidence for any therapeutic superiority for miglustat and a substantial side effect burden. </p> <p>To choose among the three approved enzyme replacement therapies, the evidence from randomized controlled studies suggests that, in treatment‐naïve patients, or after treatment interruption longer than one year, these agents are equipotent during the initial year of treatment for increasing haemoglobin concentration and platelet counts in cytopenic patients, for decreasing splenomegaly and hepatomegaly, and for achieving decreases in serum biomarkers such as chitotriosidase or CCL18‐PARC. Over the same period, there appears to be no obvious difference in the safety profile, particularly as regards infusion‐related hypersensitivity reactions. We cannot extend the impression of safety equivalence beyond the duration of the studies as the products differ in the likelihood of the development of enzyme replacement therapy antibodies (<a href="./references#CD010324-bbs2-0011" title="ZimranA , PastoresGM , Tylki‐SzymanskaA , HughesDA , ElsteinD , MardachR , et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. American Journal of Hematology2013;88(3):172‐8. [PUBMED: 23339116] ">Zimran 2013b</a>). This may have safety and efficacy implications, once a longer clinical experience is acquired. We conclude that on the basis of the randomized controlled studies we have reviewed, there is no evidence supporting the choice of one therapy over another for the treatment of naïve patients, leaving clinicians free to make recommendations to patients on the basis of non‐medical considerations such as cost. </p> </section> <h3 class="title" id="CD010324-sec-0099">Implications for research</h3> <section id="CD010324-sec-0099"> <p>It is virtually certain that, despite the rarity of the disease, additional candidate therapies for type 1 Gaucher disease (as well as for the neuronopathic variants) will continue to emerge. Eliglustat, an oral substrate synthesis inhibition therapy (SSIT), for which two‐year results of an extended phase II study (26 participants) have been published (<a href="./references#CD010324-bbs2-0059" title="LukinaE , WatmanN , ArreguinEA , DragoskyM , IastrebnerM , RosenbaumH , et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz‐112638) treatment: 2‐year results of a phase 2 study. Blood2010;116(20):4095‐8. [PUBMED: 20713962] ">Lukina 2010</a>) and five‐year results presented at the WORLD Lysosomal Disease Network Symposium (February 2013) appears to replicate the haematological, visceral, and biomarker responses described above for enzyme replacement therapies. Eliglustat is the focus of two phase III randomized controlled studies, one of which has very recently been published in full (and will be assessed for eligibility in a future update of this review) and one which will be published in full in the very near future. In one of these studies, eliglustat is compared to a placebo arm in treatment‐naïve patients ('ENGAGE'); and in the other to an imiglucerase control arm in a switch study ('ENCORE') (<a href="./references#CD010324-bbs2-0013" title="CoxTM , DrelichmanG , CravoR , BalwaniM , BurrowT , MartinsAM , et al. Encore: a multi‐national, randomized, controlled, open‐label non‐inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 (GD1) patients on enzyme replacement therapy (ERT) who have reached therapeutic goals [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐598. [CENTRAL: 977637; CRS: 5500125000000581] ">Encore 2013</a>; <a href="./references#CD010324-bbs2-0012" title="Ben TurkiaHMF , LukinaE , AmatoD , BarisH , DasoukiM , GhosnM , et al. Engage: a phase 3, randomized, double blind, placebo controlled, multi center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1: 9 month results [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐596. [CENTRAL: 977640; CRS: 5500125000000584] DasoukaM , LukinaE , Ben DridiMF , AmatoD , BarisH , GhosnM , et al. Effects of oral eliglustat on bone disease in gaucher disease type 1: results from the randomized, placebo‐controlled engage trial [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐597. [CENTRAL: 977636; CRS: 5500125000000580] MistryPK , LukinaE , Ben TurkiaH , AmatoD , BarisH , DasoukiM , et al. Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial. JAMA2015;313(7):695‐706. ">Engage 2015</a>). There is intense interest in pharmacological chaperone therapy (PCT) with one pilot study with ambroxol recently completed in Israel (<a href="./references#CD010324-bbs2-0079" title="ZimranA , AltarescuG , ElsteinD . Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood cells, molecules &amp; diseases2013;50(2):134‐7. [PUBMED: 23085429] ">Zimran 2013a</a>). This therapy prevents the degradation of the defective enzyme in the endoplasmic reticulum and allows proper folding and trafficking, by acting as reversible competitive inhibitors to glucocerebrosidase (<a href="./references#CD010324-bbs2-0066" title="OulaidiF , Front‐DeschampsS , GallienneE , LesellierE , IkedaK , AsanoN , et al. Second‐generation iminoxylitol‐based pharmacological chaperones for the treatment of Gaucher disease. ChemMedChem2011;6(2):353‐61. [PUBMED: 21275057] ">Oulaidi 2011</a>). Pre‐clinical interest in small molecule proteostasis modulators, nonsense mutation suppression and gene modification therapy may also become clinically relevant in the future (<a href="./references#CD010324-bbs2-0036" title="DietzHC . New therapeutic approaches to mendelian disorders. The New England journal of medicine2010;363(9):852‐63. [PUBMED: 20818846] ">Dietz 2010</a>). </p> <p>Is the current paradigm for evidence‐based medicine in which observational cohort studies and patient registry results are devalued relative to randomised controlled studies necessarily best adapted for comprehensively evaluating new treatments for rare, chronic conditions such as type 1 Gaucher disease, where the clinical course is protracted and disease complications are sporadic and unpredictable? When applied to chronic metabolic disorders, randomised controlled studies are rarely sustainable for more than a few years because of expense and the need for a rapid determination as to whether the candidate treatment will be a viable commercial product. A four‐arm randomised controlled study with 5000 participants to determine the "long‐term" effects of diabetes medications in people older than 30 years of age, projects an average follow up of 4.8 years (<a href="./references#CD010324-bbs2-0065" title="NathanDM , BuseJB , KahnSE , Krause‐SteinraufH , LarkinME , StatenM , et al. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care2013;36(8):2254‐61. [PUBMED: 23690531] ">Nathan 2013</a>); and the six‐year ORIGIN randomised controlled study (12,500 participants with pre‐ or early diabetes) is reputed to be the world’s longest for this disorder (<a href="./references#CD010324-bbs2-0039" title="GersteinHC , BoschJ , DagenaisGR , DíazR , JungH , MaggioniAP , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. ">Gerstein 2012</a>). When sentinel clinical events may not occur for many years after starting treatment, as is often the case in people with type 1 Gaucher disease, randomised controlled studies are usually dependent on surrogate end points such as laboratory tests or organ volume measurements whose relevance to clinically important end points may be indirect and even tenuous. Thus, as shown in this report, randomised controlled studies can establish efficacy and non‐inferiority to a sufficient level to satisfy the requirements of evidence‐based medicine, but are less likely to be able to establish superiority and effectiveness (defined as the ability of an intervention to produce a clinical benefit in actual practice) necessary to comply with the demands of value‐based medicine (<a href="./references#CD010324-bbs2-0021" title="BlackN . Why we need observational studies to evaluate the effectiveness of health care. BMJ (Clinical research ed.)1996;312(7040):1215‐8. [PUBMED: 8634569] ">Black 1996</a>; <a href="./references#CD010324-bbs2-0069" title="ResnickD , BozicKJ . Meta‐analysis of Trials of Recombinant Human Bone Morphogenetic Protein‐2: What Should Spine Surgeons and Their Patients Do With This Information?. Annals of Internal Medicine2013;158(12):912‐3. [PUBMED: 23778909] ">Resnick 2013</a>). In the case of Gaucher disease, it is unlikely that any randomised controlled study will successfully define the effect of current or future treatments on important outcomes such as Parkinsonism, malignancy, quality of life and mortality. This need can be better met by strengthening existing rare disease patient registries: to include mandatory participation in order to minimize selection bias; site visits for data verification; innovative statistical analysis such as propensity scoring and case‐control matching (<a href="./references#CD010324-bbs2-0027" title="ColeJA , TaylorJS , HangartnerTN , WeinrebNJ , MistryPK , KhanA . Reducing selection bias in case‐control studies from rare disease registries. Orphanet Journal of Rare Diseases2011;6:61. [PUBMED: 21910867] ">Cole 2011</a>); data submitted by patients; and, regardless of sponsorship, open data access (<a href="./references#CD010324-bbs2-0048" title="HollakCE , AertsJM , AymeS , ManuelJ . Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet Journal of Rare Diseases2011;6:16. [PUBMED: 21496291] ">Hollak 2011</a>; <a href="./references#CD010324-bbs2-0055" title="KrumholzHM , RossJS , GrossCP , EmanuelEJ , HodshonB , RitchieJD , et al. A historic moment for open science: the yale university open data access project and medtronic. Annals of Internal Medicine2013;158(12):910‐1. [PUBMED: 23778908] ">Krumholz 2013</a>) </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010324-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010324-sec-0022"></div> <section id="CD010324-sec-0023"> <h3 class="title" id="CD010324-sec-0023">Description of the condition</h3> <p>Gaucher disease (GD) is one of the most common lysosomal disorders, affecting approximately 1 out of 75,000 births worldwide (<a href="./references#CD010324-bbs2-0061" title="MeiklePJ , HopwoodJJ , ClagueAE , CareyWF . Prevalence of lysosomal storage disorders. JAMA1999;281(3):249‐54. [PUBMED: 9918480] ">Meikle 1999</a>), although the reported incidence and birth prevalence of such diseases figures vary considerably. It is an inherited autosomal recessive trait, and is most prevalent amongst Ashkenazi Jews (<a href="./references#CD010324-bbs2-0043" title="GrabowskiGA . Gaucher disease: gene frequencies and genotype/phenotype correlations. Genetic testing1997;1(1):5‐12. [PUBMED: 10464619] ">Grabowski 1997</a>) in whom the frequency of heterozygote carriers is estimated to be as high as 6% to 10% (<a href="./references#CD010324-bbs2-0018" title="BeutlerE , NguyenNJ , HennebergerMW , SmolecJM , McPhersonRA , WestC , et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. American Journal of Human Genetics1993;52(1):85‐8. [PUBMED: 8434610] ">Beutler 1993</a>). Gaucher disease is classified into three major phenotypes based on clinical features, age of onset, and the degree of organ involvement (<a href="./references#CD010324-bbs2-0044" title="GrabowskiGA . Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet2008;372(9645):1263‐71. ">Grabowski 2008</a>). Because all affected individuals may experience enlargement of the liver and spleen and involvement of skeletal system and bone marrow, other features are used for categorization into the three types. Type 1 (GD1) (non‐neuronopathic), the most prevalent form in Western countries, is characterized by sparing of the central nervous system (CNS) ‐ a feature that differentiates it from type 2 (GD2) (acute‐neuronopathic) and type 3 (GD3) (subacute‐neuronopathic) variants. However, intermediate phenotypes of GD are recognized, mainly between type 2 and type 3 (<a href="./references#CD010324-bbs2-0028" title="ConradiN , KyllermanM , ManssonJE , PercyAK , SvennerholmL . Late‐infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings. Acta Neuropathologica1991;82(2):152‐7. [PUBMED: 1718128] ">Conradi 1991</a>), and the different types of GD may alternatively be considered as part of a phenotypic continuum (<a href="./references#CD010324-bbs2-0025" title="CherinP , SedelF , MignotC , SchupbachM , Gourfinkel‐AnI , VernyM , et al. Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed? [Les manifestations neurologiques de la maladie de Gaucher de type 1: vers une remise en cause de la classification actuelle?]. Revue Neurologique2006;162(11):1076‐83. [PUBMED: 17086144] ">Cherin 2006</a>; <a href="./references#CD010324-bbs2-0073" title='SidranskyE . Gaucher disease: complexity in a "simple" disorder. Molecular Genetics and Metabolism2004;83(1‐2):6‐15. [PUBMED: 15464415] '>Sidransky 2004</a>) </p> <p>While GD is caused by an inborn defect of glycosphingolipid metabolism due to a deficiency of acid ß‐glucocerebrosidase in the lysosome (<a href="./references#CD010324-bbs2-0022" title="BradyRO , KanferJN , BradleyRM , ShapiroD . Demonstration of a deficiency of glucocerebroside‐cleaving enzyme in Gaucher's disease.. The Journal of Clinical Investigation July;45(7):1112‐5. ">Brady 1966</a>), the molecular link between the consequential clinico‐pathological effects of this enzyme defect and the complex multisystem disorder is not fully understood and remains the subject of intensive study, such as linking specific mutations to clinical severity (<a href="./references#CD010324-bbs2-0019" title="BeutlerE . Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatrica (Oslo, Norway : 1992). Supplement2006;95(451):103‐9. [PUBMED: 16720474] ">Beutler 2006</a>). Reduced capacity to degrade exogenous and endogenous glycosphingolipids induces the accumulation of glucocerebroside within macrophages with the development of the pathognonomic 'storage' macrophages, often referred to as 'Gaucher cells' (<a href="./references#CD010324-bbs2-0058" title="LeeRE . The pathology of Gaucher disease. Progress in Clinical and Biological Research1982;95:177‐217. [PUBMED: 7122634] ">Lee 1982</a>). These cells are found principally in the bone marrow, spleen and liver. Prominent clinical features of GD are anaemia, bleeding (mostly attributed to thrombocytopenia), enlargement of the spleen and liver, osteopenia (<a href="./references#CD010324-bbs2-0076" title="StowensDW , TeitelbaumSL , KahnAJ , BarrangerJA . Skeletal complications of Gaucher disease. Medicine1985;64(5):310‐22. [PUBMED: 4033409] ">Stowens 1985</a>) and bone pain. In GD2 and GD3, the neurological manifestations are usually dominant, and neurodegenerative processes lead to tremor, parkinsonism, and abnormal eye movements. Other features of GD are osteonecrosis (which characteristically causes severe bone pain and bone crises), retarded growth (<a href="./references#CD010324-bbs2-0052" title="KaplanP , AnderssonHC , KacenaKA , YeeJD . The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Archives of Pediatrics &amp; Adolescent Medicine2006;160(6):603‐8. [PUBMED: 16754822] ">Kaplan 2006</a>; <a href="./references#CD010324-bbs2-0053" title="KauliR , ZaizovR , LazarL , PertzelanA , LaronZ , GalatzerA , et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Israel Medical Association Journal2000;2(2):158‐63. [PUBMED: 10804944] ">Kauli 2000</a>), and, occasionally, lung and even kidney disease. Given the description of GD1 as non‐neuronopathic, it is noteworthy that it has been recently shown that carriers of GD, as well as people with the disease, are at a greatly increased risk of parkinsonism (<a href="./references#CD010324-bbs2-0041" title="Goker‐AlpanO , SchiffmannR , LaMarcaME , NussbaumRL , McInerney‐LeoA , SidranskyE . Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics2004;41(12):937‐40. [PUBMED: 15591280] ">Goker‐Alpan 2004</a>; <a href="./references#CD010324-bbs2-0073" title='SidranskyE . Gaucher disease: complexity in a "simple" disorder. Molecular Genetics and Metabolism2004;83(1‐2):6‐15. [PUBMED: 15464415] '>Sidransky 2004</a>) </p> </section> <section id="CD010324-sec-0024"> <h3 class="title" id="CD010324-sec-0024">Description of the intervention</h3> <p>Complementation of deficient enzyme activity in the lysosomal compartment of macrophages is brought about by receptor‐mediated glycoprotein uptake, via mannose receptors on the cell surface membrane; this mechanism forms the basis for enzyme replacement therapy (ERT) (<a href="./references#CD010324-bbs2-0062" title="MistryPK , WraightEP , CoxTM . Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet1996;348(9041):1555‐9. [PUBMED: 8950883] ">Mistry 1996</a>). Macrophage‐targeted (mannose‐terminal) human glucocerebrosidase is generally accepted as the first line therapy for GD. Recombinant enzymes, such as imiglucerase (Cerezyme<sup>®</sup>, Genzyme Corporation, Cambridge, MA) taliglucerase alfa (Elelyso<sup>®</sup>, Protalix Biotherapeutics, Carmiel, Israel) or velaglucerase alfa (VPRIV<sup>®</sup>, Shire HGT, Cambridge MA), are administered intravenously. The treatment dose usually varies from 15 units/kg to 60 units/kg body weight (<a href="./references#CD010324-bbs2-0067" title="PastoresGM . Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy2010;24(1):41‐7. [PUBMED: 20055531] ">Pastores 2010</a>). Most individuals respond well, with a prompt reduction in liver and spleen volume, increased haemoglobin concentrations and platelet counts; moreover, skeletal pain and episodic symptoms originating from the involvement of bone may also resolve (<a href="./references#CD010324-bbs2-0047" title="HollakCE , vom DahlS , AertsJM , BelmatougN , BembiB , CohenY , et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells, Molecules &amp; Diseases2010;44(1):41‐7. [PUBMED: 19804996] ">Hollak 2010</a>). These beneficial effects are usually apparent by six months of administration but, in some people, longer periods of treatment may be required for other manifestations of disease to improve. Biochemical markers of the disease in the plasma show marked reduction upon effective treatment. Usually the response to administered enzyme reaches a plateau within the first few years. Of note, the administered enzymes do not cross the blood‐brain barrier (BBB), and the neurologic manifestations seen in GD2 and GD3 are refractory to this treatment. The use of ERT is considered safe, with few hypersensitivity reactions, and rare cases of anaphylaxis (<a href="./references#CD010324-bbs2-0074" title="StarzykK , RichardsS , YeeJ , SmithSE , KingmaW . The long‐term international safety experience of imiglucerase therapy for Gaucher disease. Molecular Genetics and Metabolism2007;90(2):157‐63. [PUBMED: 17079176] ">Starzyk 2007</a>). Unwanted effects include temporary weight gain and insulin resistance (<a href="./references#CD010324-bbs2-0057" title="LangeveldM , deFostM , AertsJM , SauerweinHP , HollakCE . Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells, Molecules &amp; Diseases2008;40(3):428‐32. [PUBMED: 17950007] ">Langeveld 2008</a>). At present, it is unclear whether prolonged survival due to therapy in affected individuals is accompanied by salutary effects or other effects on the development of complications of GD, such as multiple myeloma (<a href="./references#CD010324-bbs2-0070" title="RosenbloomBE , WeinrebNJ , ZimranA , KacenaKA , CharrowJ , WardE . Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood2005;105(12):4569‐72. [PUBMED: 15718419] ">Rosenbloom 2005</a>) and Parkinson disease (<a href="./references#CD010324-bbs2-0023" title="BultronG , KacenaK , PearsonD , BoxerM , YangR , SatheS , et al. The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease2010;33(2):167‐73. [PUBMED: 20177787] ">Bultron 2010</a>), which occur with increased frequency in adults. </p> <p>Substrate reduction therapy (SRT) has been explored as an alternative treatment for GD. Substrate reducing agents were used to inhibit the biosynthesis of glucocerebroside (<a href="./references#CD010324-bbs2-0029" title="CoxT , LachmannR , HollakC , AertsJ , vanWeelyS , HrebicekM , et al. Novel oral treatment of Gaucher's disease with N‐butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet2000;355(9214):1481‐5. [PUBMED: 10801168] ">Cox 2000</a>), thereby ameliorating the pathological accumulation of glycolipids and cognate metabolites in GD (<a href="./references#CD010324-bbs2-0068" title="PlattFM , NeisesGR , DwekRA , ButtersTD . N‐butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. The Journal of Biological Chemistry1994;269(11):8362‐5. [PUBMED: 8132559] ">Platt 1994;</a><a href="./references#CD010324-bbs2-0051" title="InokuchiJ , RadinNS . Preparation of the active isomer of 1‐phenyl‐2‐decanoylamino‐3‐morpholino‐1‐propanol, inhibitor of murine glucocerebroside synthetase. Journal of Lipid Research1987;28(5):565‐71. [PUBMED: 2955067] ">Inokuchi 1987</a>). At present, the only approved agent in this class is miglustat (Zavesca<sup>®</sup>, Actelion Pharmaceuticals US, San Francisco, CA), which is licensed as a second‐line agent in adults who are unsuitable for or unwilling to take ERT. The drug, an iminosugar, has the advantage of being administered orally; however, it has a higher frequency of unwanted effects, such as tremor and gastrointestinal complaints, and, although comparative studies have never been performed, may be less effective for several aspects of GD than the available ERTs (<a href="./references#CD010324-bbs2-0030" title="CoxTM , AertsJM , AndriaG , BeckM , BelmatougN , BembiB , et al. The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: a position statement. Journal of Inherited Metabolic Disease2003;26(6):513‐26. [PUBMED: 14605497] ">Cox 2003;</a><a href="./references#CD010324-bbs2-0056" title="KuterDJ , MehtaA , HollakCE , GiraldoP , HughesD , BelmatougN , et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells, Molecules &amp; Diseases2013;51(2):116‐24. [PUBMED: 23683771] ">Kuter 2013</a>). Unlike ERT, miglustat can partially cross the BBB (<a href="./references#CD010324-bbs2-0014" title="AertsJM , HollakCE , BootRG , GroenerJE , MaasM . Substrate reduction therapy of glycosphingolipid storage disorders. Journal of Inherited Metabolic Disease2006;29(2‐3):449‐56. [PUBMED: 16763917] ">Aerts 2006</a>). Miglustat has also been explored in people with GD3, but no clinically meaningful neurological benefit was observed (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). However, the trial was small and participants differed substantially in disease severity. Eliglustat tartrate (Genzyme, a Sanofi Corporation, Cambridge, MA, USA), a potent inhibitor of glucosylceramide synthase that is chemically unrelated to miglustat, is also orally active (<a href="./references#CD010324-bbs2-0060" title="McEachernKA , FungJ , KomarnitskyS , SiegelCS , ChuangWL , HuttoE , et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Molecular Genetics and Metabolism2007;91(3):259‐67. [PUBMED: 17509920] ">McEachern 2007</a>) and is now in the late stage of phase 3 clinical trials for the treatment of GD1 (<a href="./references#CD010324-bbs2-0031" title="CoxTM . Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Current Opinion in Investigational Drugs2010;11(10):1169‐81. [PUBMED: 20872320] ">Cox 2010</a>; <a href="./references#CD010324-bbs2-0059" title="LukinaE , WatmanN , ArreguinEA , DragoskyM , IastrebnerM , RosenbaumH , et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz‐112638) treatment: 2‐year results of a phase 2 study. Blood2010;116(20):4095‐8. [PUBMED: 20713962] ">Lukina 2010</a>) ‐ as a substrate for P‐glycoprotein, eliglustat tartrate is extruded from the central nervous system (CNS). </p> </section> <section id="CD010324-sec-0025"> <h3 class="title" id="CD010324-sec-0025">Why it is important to do this review</h3> <p>In considering clinical studies, evidence for efficacy of ERT and SRT in GD is unusually sparse. This is somewhat understandable, given that the condition is an ultra‐orphan multisystem chronic disorder with diverse clinical manifestations and severity. Although there is much anecdotal and experiential conviction that ERT for GD has long‐term benefits, in order to substantiate the effectiveness of enzyme therapy in GD, there is need for a better corpus of evidence, including clinical trials that, due to the rarity, heterogeneity and chronicity of this disorder may or may not necessarily be able to conform to accepted criteria for evidence‐based medicine. Nevertheless, a critical examination of what evidence from randomized clinical studies is now available in GD is essential as a basis for future studies. Given the exceptional commercial interest in this disorder, a robust platform for evaluating long‐term efficacy and other outcomes is desirable. The recent development of new products (miglustat, velaglucerase‐alfa, taliglucerase‐alfa, eliglustat tartrate) as alternatives to imiglucerase raises questions as to whether the multiplicity of new non‐inferior agents offers biological benefits beyond potential cost savings (a significant consideration considering the huge expense of these treatments) and redundancy in case of a supply interruption such as occurred in 2009. Here we use the methodology of the Cochrane collaboration to examine the current evidentiary status of the four approved therapies currently prescribed for more than 7000 people with GD worldwide. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010324-sec-0026" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010324-sec-0026"></div> <p> <ol id="CD010324-list-0001"> <li> <p>To assess the effectiveness and safety of ERTs and SRTs.</p> </li> <li> <p>To identify knowledge gaps which may result in new areas of research.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010324-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010324-sec-0027"></div> <section id="CD010324-sec-0028"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010324-sec-0029"> <h4 class="title">Types of studies</h4> <p>All randomized and quasi‐randomized controlled studies (including open‐label trials and cross‐over studies). </p> </section> <section id="CD010324-sec-0030"> <h4 class="title">Types of participants</h4> <p>Individuals with GD of any age (specifically including children) and of any disease severity. </p> </section> <section id="CD010324-sec-0031"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD010324-list-0002"> <li> <p>ERT (of any dose) compared with SRT (of any dose)</p> </li> <li> <p>The addition of SRT to ERT compared with ERT alone</p> </li> <li> <p>ERT or SRT, or both (of different doses), compared with no treatment</p> </li> <li> <p>Comparison of different ERTs (evaluated in this review)</p> </li> <li> <p>Comparison of different SRTs</p> </li> </ol> </p> </section> <section id="CD010324-sec-0032"> <h4 class="title">Types of outcome measures</h4> <section id="CD010324-sec-0033"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010324-list-0003"> <li> <p>Frequency of side effects</p> </li> <li> <p>Haemoglobin and platelet counts</p> </li> <li> <p>Hepatosplenomegaly</p> <ol id="CD010324-list-0004"> <li> <p>Spleen size (e.g. multiples of normal, tissue mL/kg body weight or mL)</p> </li> <li> <p>Liver size (e.g. multiples of normal, tissue mL/kg body weight or mL)</p> </li> </ol> </li> </ol> </p> </section> <section id="CD010324-sec-0034"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010324-list-0005"> <li> <p>Change in biomarker levels</p> <ol id="CD010324-list-0006"> <li> <p>Chitotriosidase (nmol/ml/hr)</p> </li> <li> <p>CCL18‐PARC</p> </li> <li> <p>Angiotensin‐converting enzyme (ACE) (international units (IU)/L)</p> </li> <li> <p>Tartrate resistant acid phosphatase (TRAP) (IU/L) levels</p> </li> </ol> </li> <li> <p>Skeletal outcomes</p> <ol id="CD010324-list-0007"> <li> <p>Frequency of bone pain</p> </li> <li> <p>Frequency of bone crisis events (events in which severe pain is experienced due to infarction of the bones) </p> </li> <li> <p>Bone density scores (z scores and t scoresֹׁׁ)ׁ</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD010324-sec-0035"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010324-sec-0036"> <h4 class="title">Electronic searches</h4> <p>Relevant trials were identified by searching the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register using the term: gauchers. </p> <p>The Inborn Errors of Metabolism Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated with each new issue of <i>The Cochrane Library</i> ), quarterly searches of MEDLINE and the prospective handsearching of one journal ‐ J<i>ournal of Inherited Metabolic Disease</i>. Unpublished work is identified by searching through the abstract books of the Society for the Study of Inborn Errors of Metabolism conference and the SHS Inborn Error Review Series. For full details of all searching activities for the register, please see the relevant section of the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/CF/frame.html" target="_blank">Cystic Fibrosis and Genetic Disorders Group Module</a>. </p> <p>Additional searches were conducted on <a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> for any ongoing studies with potential interim results, and through MEDLINE (PubMed) (<a href="#CD010324-sec-0102">Appendices</a>). </p> <p>Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register: 07 August 2014. </p> </section> <section id="CD010324-sec-0037"> <h4 class="title">Searching other resources</h4> <p>The bibliographic references of all retrieved literature were reviewed for additional reports of studies. In addition, the authors contacted experts in the field in an attempt to retrieve any further relevant data and papers. </p> </section> </section> <section id="CD010324-sec-0038"> <h3 class="title" id="CD010324-sec-0038">Data collection and analysis</h3> <section id="CD010324-sec-0039"> <h4 class="title">Selection of studies</h4> <p>Two authors (ES and LD) independently assessed and discussed the papers identified by the initial searches in order to decide whether they met the inclusion criteria. </p> </section> <section id="CD010324-sec-0040"> <h4 class="title">Data extraction and management</h4> <p>Two authors (ES and LD) independently extracted the data using standard acquisition forms, that included information about: </p> <p> <ol id="CD010324-list-0008"> <li> <p>methods of the study (type of study, whether randomization was applied, number of participants and dropouts); </p> </li> <li> <p>characteristics of the study population;</p> </li> <li> <p>type of intervention;</p> </li> <li> <p>data for assessing the risk of bias (methods of randomization, whether blinding was applied (and who was blinded), type of sequence generation, and type of allocation concealment); </p> </li> <li> <p>outcomes and results (means, standard deviations (SD) or standard errors (SE).</p> </li> </ol> </p> </section> <section id="CD010324-sec-0041"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the included studies using the Cochrane risk of bias assessment tool, focusing on the following domains (<a href="./references#CD010324-bbs2-0046" title="HigginsJPT , Altman DG(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> <section id="CD010324-sec-0042"> <h5 class="title">Assessment of sequence generation</h5> <p> <ol id="CD010324-list-0009"> <li> <p>low: if allocation sequence is suitable to prevent selection bias (i.e. computer‐generated lists, coin tossing, shuffling cards or envelopes, random number table, etc); </p> </li> <li> <p>high: if allocation sequence could be related to prognosis and thus introduce selection bias (i.e. date of admission, clinical judgement, participant preference, results of laboratory tests, availability of intervention, date of birth, etc); </p> </li> <li> <p>unclear: if there is insufficient information regarding the sequence generation.</p> </li> </ol> </p> </section> <section id="CD010324-sec-0043"> <h5 class="title">Assessment of allocation concealment</h5> <p> <ol id="CD010324-list-0010"> <li> <p>low: if investigators were shielded from predicting the assignment of participants into the intervention groups (i.e. central randomization was done by telephone or by a pharmacy, identical and sequentially numbered drug containers or sequentially numbered sealed and opaque envelopes); </p> </li> <li> <p>high: if investigators were not shielded from predicting the assignment of participants into the intervention groups (i.e. non‐opaque envelopes, open allocation schedule, etc); </p> </li> <li> <p>unclear: if the method of concealment is not described.</p> </li> </ol> </p> </section> <section id="CD010324-sec-0044"> <h5 class="title">Assessment of blinding</h5> <p> <ol id="CD010324-list-0011"> <li> <p>low: if no blinding was done, but outcome was not likely to be influenced by the lack of blinding; or if blinding was ensured and was unlikely to be broken; </p> </li> <li> <p>high: if no blinding was done, and outcome was likely to be affected by the lack of blinding; or blinding was attempted but could have been broken; </p> </li> <li> <p>unclear: if the method of blinding is not described.</p> </li> </ol> </p> </section> <section id="CD010324-sec-0045"> <h5 class="title">Incomplete data</h5> <p>We considered whether it was stated how many participants were lost to follow‐up, and if reasons for this were given; when loss to follow up did occur, we checked whether an intention‐to‐treat‐analysis was performed. According to these criteria, we defined three levels of risk of bias: </p> <p> <ol id="CD010324-list-0012"> <li> <p>low risk: if the number or reasons (or both) for loss to follow up were mentioned, and if intention‐to‐treat‐analysis was carried out; </p> </li> <li> <p>high risk: if number or reasons (or both) for loss to follow up were not mentioned, or intention‐to‐treat‐analysis was not carried (or both); </p> </li> <li> <p>unclear risk: if the original study did not specify the way loss to follow‐up was handled. </p> </li> </ol> </p> </section> <section id="CD010324-sec-0046"> <h5 class="title">Selective outcome reporting</h5> <p>We assessed the consistency between the outcomes originally planned to be reported during the study, and those actually reported in the published paper, by comparing the trial protocols and registries with the information in the final publication. When trial protocols were not available, the methods section of the publication were compared to the published results. </p> </section> <section id="CD010324-sec-0047"> <h5 class="title">Other sources of bias</h5> <p>We reviewed relevant studies for other potential sources of bias, such as: deviation from study protocol; early cessation of the study; selective reporting of subgroups; or a bias due to poor delivery of the interventions. </p> </section> </section> <section id="CD010324-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>We have analysed the continuous data by calculating treatment effects' mean difference (MD) and the corresponding 95% CIs. If relevant, in future updates of this review, we plan to analyse dichotomous data by calculating the odds ratio (OR) and 95% confidence intervals (CIs). </p> </section> <section id="CD010324-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>If cross‐over studies are included in future updates of this review, we plan to use the methods recommended by Elbourne (<a href="./references#CD010324-bbs2-0037" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>) to conduct a meta‐analysis combining results from such studies. Similarly, if cluster‐randomized studies are identified and included, we will check these for unit of analysis errors based on the advice given in chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010324-bbs2-0046" title="HigginsJPT , Altman DG(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> <section id="CD010324-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>In four of the eight included studies (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>), the data were not in the format of mean with SD or SE, or were incompletely reported. We contacted the authors of these manuscripts, and in three cases obtained further data (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). In one instance, the authors were unable to provide original data (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). In this case we extracted means from the original figures and estimated SDs from the reported statistical probability values, assuming normal distribution of the variables. </p> <p>In future updates of the review, if some of the numerical data are missing from further identified studies (i.e. SDs), we will contact the original investigators and request these data. If we are unable to retrieve these data, we will attempt to calculate these by utilising the available data (e.g. when a SD is not reported, calculation may be possible based on given CIs, means, and the number of participants). If this is not possible, we will attempt to impute SDs based on similar studies (i.e. interventions, time points, population). </p> </section> <section id="CD010324-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>Since a meta‐analysis was not carried out, we did not assess heterogeneity between the studies mathematically. In a visual assessment of the forest plots, no major heterogeneity between studies was noted. In future updates of this review, if we conduct a meta‐analysis, we will assess the forest plots visually, and will use the I<sup>2</sup> statistic and the Chi<sup>2</sup> test and its corresponding P value, as stated in chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010324-bbs2-0034" title="DeeksJ , HigginsJ , AltmanD . Chapter 9 Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD010324-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>As per protocol, since we identified fewer than 10 studies, we did not construct a funnel plot. Therefore, no comments regarding reporting biases are discussed in this review. If future updates of this review include 10 or more studies, we will assess potential publication bias by constructing and assessing the symmetry of a funnel plot. </p> </section> <section id="CD010324-sec-0053"> <h4 class="title">Data synthesis</h4> <p>Time points originally considered in the analysis 0 to under 3 months, 3 months to under 6 months, 6 months to under 9 months, 9 months to under 12 months, 12 months to under 18 months, and 18 months up to 24 months. For haemoglobin, platelet counts, disease biomarkers, liver and spleen volumes, the latter two time points are evaluated in the current review. Since visceral effects and improvement in blood counts in the first 0 to 6 months of treatment add no worthwhile measure of clinical efficacy, especially in the case of biomarkers such as chitotriosidase, and because data relevant to this time frame was only reported by one group (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>), we have chosen not to include it in the analyses. A fixed‐effect model will be used to synthesize data in future updates of this manuscript, if possible. </p> </section> <section id="CD010324-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p> <ol id="CD010324-list-0013"> <li> <p>Different doses or regimens (or both) of therapy: up to 30 international units/kg/2 weeks; 30 to 60 international units/kg/2 weeks; and above 60 international units/kg/2 weeks </p> </li> <li> <p>Different ERTs and SRTs</p> </li> <li> <p>Splenectomised individuals compared with those having an intact spleen</p> </li> </ol> </p> </section> <section id="CD010324-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>As per protocol, a sensitivity analysis (excluding studies with an overall high risk of bias) was not performed, since less than 10 studies were identified. However, a sensitivity analysis was conducted excluding individuals reported in one study who patently did not have GD. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010324-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010324-sec-0056"></div> <section id="CD010324-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD010324-sec-0058"> <h4 class="title">Results of the search</h4> <p>A total of 488 studies and five conference abstracts were retrieved by the electronic search, and screened for eligibility. Eight studies met the inclusion criteria and were included in the analysis (<a href="#CD010324-fig-0001">Figure 1</a>), yielding a total of 300 adults and children (males and females), of multinational origin. Studies were excluded if they were not randomized, not controlled, or if an irrelevant intervention was assessed. </p> <div class="figure" id="CD010324-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010324-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>No placebo‐controlled studies were found.</p> </section> <section id="CD010324-sec-0059"> <h4 class="title">Included studies</h4> <p>Eight studies fulfilled the inclusion criteria for this review. Six studies (234 participants) compared different ERTs (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>); and two studies compared the addition of SRT to ERT compared with ERT alone (66 participants) (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). No trials compared exactly the same treatments. There were a range of ERTs used (velaglucerase, imiglucerase, alglucerase or taliglucerase) which were compared to each other or the same ERT but at different doses; and one SRT used (miglustat). </p> <p>Half of the included studies evaluated pre‐treated or stabilized individuals (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>; <a href="./references#CD010324-bbs2-0009" title="ElsteinD , AbrahamovA , Hadas‐HalpernI , MeyerA , ZimranA . Low‐dose low‐frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM: Monthly Journal of the Association of Physicians1998;91(7):483‐8. [PUBMED: 9797931] ">Elstein 1998</a>). Seven studies enrolled people with GD1; one study (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>) was restricted to people with GD3. Unlike the others, the primary focus of this study was on neurological rather than systemic responses. </p> <p>Four studies enrolled participants who were either ERT or SRT naïve or who had an interruption of prior ERT of at least 12 months. In one of these, two participants without evidence of GD were included (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). Sub‐analyses, excluding these participants, were therefore carried out. </p> <p>Of note, four of the included studies that enrolled individuals who were already receiving ERT were not primary efficacy studies, but rather were designed to test the effect of a new intervention on maintenance of previously achieved therapeutic gains. </p> <p>For more details regarding the included studies, please see the <a href="./references#CD010324-sec-0113" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD010324-sec-0060"> <h4 class="title">Excluded studies</h4> <p>Two non‐randomized studies and one investigating alendronate disodium were excluded from the analysis (<a href="./references#CD010324-bbs2-0009" title="ElsteinD , AbrahamovA , Hadas‐HalpernI , MeyerA , ZimranA . Low‐dose low‐frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM: Monthly Journal of the Association of Physicians1998;91(7):483‐8. [PUBMED: 9797931] ">Elstein 1998</a>; <a href="./references#CD010324-bbs2-0010" title="WenstrupRJ , BaileyL , GrabowskiGA , MoskovitzJ , OestreichAE , WuW , et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood2004;104(5):1253‐7. [CENTRAL: 489109; CRS: 5500100000002632; PUBMED: 15010365] ">Wenstrup 2004</a>; <a href="./references#CD010324-bbs2-0011" title="ZimranA , PastoresGM , Tylki‐SzymanskaA , HughesDA , ElsteinD , MardachR , et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. American Journal of Hematology2013;88(3):172‐8. [PUBMED: 23339116] ">Zimran 2013b</a>). In the Elstein study, 28 people with GD1 received a low‐dose low‐frequency imiglucerase regimen (<a href="./references#CD010324-bbs2-0009" title="ElsteinD , AbrahamovA , Hadas‐HalpernI , MeyerA , ZimranA . Low‐dose low‐frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM: Monthly Journal of the Association of Physicians1998;91(7):483‐8. [PUBMED: 9797931] ">Elstein 1998</a>); in the Zimran study, 40 people with GD1 received different doses of velaglucerase alfa (<a href="./references#CD010324-bbs2-0011" title="ZimranA , PastoresGM , Tylki‐SzymanskaA , HughesDA , ElsteinD , MardachR , et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. American Journal of Hematology2013;88(3):172‐8. [PUBMED: 23339116] ">Zimran 2013b</a>). A further study was excluded as the intervention was not relevant (alendronate disodium) (<a href="./references#CD010324-bbs2-0010" title="WenstrupRJ , BaileyL , GrabowskiGA , MoskovitzJ , OestreichAE , WuW , et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood2004;104(5):1253‐7. [CENTRAL: 489109; CRS: 5500100000002632; PUBMED: 15010365] ">Wenstrup 2004</a>). </p> <section id="CD010324-sec-0061"> <h5 class="title">Studies awaiting classification</h5> <p>There is one study, published just immediately prior to producing the final version of this review, that is awaiting classification (<a href="./references#CD010324-bbs2-0012" title="Ben TurkiaHMF , LukinaE , AmatoD , BarisH , DasoukiM , GhosnM , et al. Engage: a phase 3, randomized, double blind, placebo controlled, multi center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1: 9 month results [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐596. [CENTRAL: 977640; CRS: 5500125000000584] DasoukaM , LukinaE , Ben DridiMF , AmatoD , BarisH , GhosnM , et al. Effects of oral eliglustat on bone disease in gaucher disease type 1: results from the randomized, placebo‐controlled engage trial [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐597. [CENTRAL: 977636; CRS: 5500125000000580] MistryPK , LukinaE , Ben TurkiaH , AmatoD , BarisH , DasoukiM , et al. Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial. JAMA2015;313(7):695‐706. ">Engage 2015</a>). Eliglustat is the focus of this phase III randomized placebo‐controlled study of treatment‐naïve patients (<a href="./references#CD010324-bbs2-0012" title="Ben TurkiaHMF , LukinaE , AmatoD , BarisH , DasoukiM , GhosnM , et al. Engage: a phase 3, randomized, double blind, placebo controlled, multi center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1: 9 month results [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐596. [CENTRAL: 977640; CRS: 5500125000000584] DasoukaM , LukinaE , Ben DridiMF , AmatoD , BarisH , GhosnM , et al. Effects of oral eliglustat on bone disease in gaucher disease type 1: results from the randomized, placebo‐controlled engage trial [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐597. [CENTRAL: 977636; CRS: 5500125000000580] MistryPK , LukinaE , Ben TurkiaH , AmatoD , BarisH , DasoukiM , et al. Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial. JAMA2015;313(7):695‐706. ">Engage 2015</a>). </p> </section> <section id="CD010324-sec-0062"> <h5 class="title">Ongoing studies</h5> <p>There is one ongoing study (<a href="./references#CD010324-bbs2-0013" title="CoxTM , DrelichmanG , CravoR , BalwaniM , BurrowT , MartinsAM , et al. Encore: a multi‐national, randomized, controlled, open‐label non‐inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 (GD1) patients on enzyme replacement therapy (ERT) who have reached therapeutic goals [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐598. [CENTRAL: 977637; CRS: 5500125000000581] ">Encore 2013</a>). This phase III randomized study compares eliglustat to a imiglucerase control arm and is expected to be published in full in the near future (<a href="./references#CD010324-bbs2-0013" title="CoxTM , DrelichmanG , CravoR , BalwaniM , BurrowT , MartinsAM , et al. Encore: a multi‐national, randomized, controlled, open‐label non‐inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 (GD1) patients on enzyme replacement therapy (ERT) who have reached therapeutic goals [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S268, Abstract no: P‐598. [CENTRAL: 977637; CRS: 5500125000000581] ">Encore 2013</a>). </p> </section> </section> </section> <section id="CD010324-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>All studies were randomized. Four of the included studies were unblinded (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>) (<a href="./references#CD010324-sec-0113" title="">Characteristics of included studies</a>). A risk of bias table was completed for randomization, allocation concealment, blinding, incomplete outcome data, and study size (<a href="./references#CD010324-sec-0113" title="">Characteristics of included studies</a>, <a href="#CD010324-fig-0002">Figure 2</a>). In most cases, the risk for adequate sequence generation and allocation concealment bias could not be assessed, due to insufficient details regarding the methods used. Only one publication (<a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>) reported a 'low risk of bias' score in all parameters assessed. Gonzalez was described as with high risk for other type of bias, due to the inclusion of two participants who proved not to have GD (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). </p> <div class="figure" id="CD010324-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010324-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010324-sec-0064"> <h4 class="title">Allocation</h4> <section id="CD010324-sec-0065"> <h5 class="title">Generation of randomization sequence</h5> <p>For four studies we assessed there to be a low risk of bias for the generation of the randomization sequence (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>) and for the remaining four, an unclear risk of bias due to insufficient data (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>; <a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>). </p> </section> <section id="CD010324-sec-0066"> <h5 class="title">Allocation concealment</h5> <p>Three studies described the allocation concealment in enough detail to be judged as to have a low risk of bias (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>). The risk of bias bias in four studies was considered unclear (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>; <a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>), and as high in the final study (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). </p> </section> </section> <section id="CD010324-sec-0067"> <h4 class="title">Blinding</h4> <p>Three studies were considered to have a high risk for this domain (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>): in one study it was stated that participants were not blinded to treatment group (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>), and in two studies an oral drug was added to IV therapy (or oral drug alone) compared to IV therapy, without reporting the use of an oral placebo (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). It is therefore plausible to assume that participants were not blinded to treatment. Three studies were described as double‐blind and one stated that observers were blinded; these four were deemed to have a low risk of bias (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). The remaining study was classified as unclear due to insufficient data (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>). </p> </section> <section id="CD010324-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Kishnani was the only study considered to have a high risk of bias for incomplete outcome reporting (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). This was decided because an intention‐to‐treat analysis was carried out, despite not meeting all criteria for such analysis. Six studies were regarded as having a low risk for bias for this domain (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). The final study was categorized as having an unclear risk of bias (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). </p> </section> <section id="CD010324-sec-0069"> <h4 class="title">Selective reporting</h4> <p>All eight studies were assessed as having a low risk for selective reporting bias.</p> </section> <section id="CD010324-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Gonzalez included participants who did not have GD and was therefore regarded as a high risk of 'other bias' (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). After careful evaluation of the Schiffmann study, it appeared that the intervention groups were not balanced in several aspects, such as sex and age of the participants (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). It was not stated in the original paper whether these differences were statistically significant. </p> </section> </section> <section id="CD010324-sec-0071"> <h3 class="title" id="CD010324-sec-0071">Effects of interventions</h3> <section id="CD010324-sec-0072"> <h4 class="title">Enzyme replacement treatment (ERT)</h4> <p>Six studies (234 participants) assessed this intervention (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). </p> <section id="CD010324-sec-0073"> <h5 class="title">Primary outcomes</h5> <section id="CD010324-sec-0074"> <h6 class="title">1. Frequency of side effects</h6> <p>All six studies (234 participants) evaluating ERT reported on side effects.</p> <p>In the Grabowski study (alglucerase versus imiglucerase), three participants (unclear from paper in which group) reported dizziness, pruritus or a skin eruption (<a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>). No discontinuation of the intervention was required. </p> <p>In the Zimran study (taliglucerase alfa), 137 adverse events were reported by 23 participants (12 in the 30 units/kg and 11 in the 60 units/kg group) (<a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). The investigators graded all adverse events as mild or moderate and transient. Nausea and headache were the most frequent. One participant in each dose group developed hypersensitivity reactions, with one of them experiencing an immediate hypersensitivity reaction and being excluded from the intention‐to‐treat efficacy analysis after pre‐dose serum IgE concentrations were found to be elevated. This participant was also subsequently determined to have a sensitivity to imiglucerase. A single participant withdrew from the study after a mast cell‐mediated hypersensitivity reaction occurred. </p> <p>In the Gonzalez study, (velaglucerase alfa), no treatment‐related hypersensitivity reactions or life‐threatening serious adverse events were described (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). Fifteen of 25 participants (six in the 60 units/kg group and nine in the 45 units/kg group) experienced at least one adverse event, of which, 14 were classified as infusion‐related. Headache, nasopharyngitis, traumatic injury, arthralgia, cough, pyrexia, dizziness, nasal congestion, influenza, bone pain and prolonged activated partial thromboplastin time (aPTT) were the most common. </p> <p>In the Ben Turkia study (imiglucerase versus velaglucerase alfa), three serious adverse events occurred in the participants receiving velaglucerase alfa (allergic dermatitis, severe prolonged aPTT and, in a child with no prior neurological history, a 15‐minute generalized tonic‐clonic seizure immediately after an infusion) (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>). All were deemed unrelated to treatment. Similar frequencies of drug‐related adverse events (most infusion‐related) were reported for the two ERTs (8 of 17 participants in the velaglucerase group; 6 of 17 participants in the imiglucerase group). One imiglucerase participant withdrew consent due to multiple infusion reactions. </p> <p>In the Kishnani study (imiglucerase), 18 serious adverse events occurred (13 in the 33 participants in the once‐every‐two‐weeks infusion group; 5 in the 62 participants in the once‐every‐four‐weeks infusion group) (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). None were graded by the investigators as infusion‐related. Fatigue, a falling haemoglobin concentration, decrease in platelet count and increasing splenomegaly, (all associated with worsening or progression of disease), were more frequent in the group infused every four weeks (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). </p> </section> <section id="CD010324-sec-0075"> <h6 class="title">2. Haemoglobin (Hb) concentrations and platelet counts (PLT)</h6> <p>All six studies (234 participants) assessing ERT evaluated the effects on Hb concentration and PLT counts. </p> <section id="CD010324-sec-0076"> <p><b>a. Haemoglobin concentration</b></p> <p>Four studies evaluated Hb in treatment‐naïve participants (see <a href="./references#CD010324-sec-0113" title="">Characteristics of included studies</a>), and two in participants who were actively receiving treatment (maintenance studies). Among treatment‐naïve, anaemic participants in the four relevant studies, increases in Hb concentration of 1.62 to 3.2 g/dL were reported over 6‐ to 12‐month observation periods. </p> <p>When treatment‐naïve participants were analysed, no significant difference was seen at nine months when comparing imiglucerase and alglucerase at 60 units/kg every two weeks (<a href="./references#CD010324-fig-0007" title="">Analysis 1.1</a>; <a href="#CD010324-fig-0003">Figure 3</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>). No significant difference was seen between imiglucerase 60 units/kg and velaglucerase alfa 60 units/kg every two weeks at nine months (<a href="./references#CD010324-fig-0007" title="">Analysis 1.1</a>; <a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>), even when participants with a history of splenectomy were excluded from the analysis. On comparing taliglucerase alfa at 30 units/kg to a 60 units/kg regimen (both approximately every two weeks), at nine months, there was no statistically significant difference (<a href="./references#CD010324-fig-0007" title="">Analysis 1.1</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). </p> <div class="figure" id="CD010324-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.1 Haemoglobin levels (9 months)." data-id="CD010324-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.1 Haemoglobin levels (9 months). </p> </div> </div> </div> <p>For velaglucerase alfa, at 12 months, there was no significant difference in Hb outcome between 45 units/kg and 60 units/kg every two weeks even after exclusion of two non‐GD participants who were erroneously included (<a href="./references#CD010324-fig-0008" title="">Analysis 1.2</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). </p> <p>In the two maintenance studies that could be assessed with our methodology (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>) ‐ in which an end‐point values analysis is reported, no statistically significant difference in Hb concentrations was observed between imiglucerase given at intervals of either two or four weeks, at the same monthly total dose, or at nine, 12 or 24 months (<a href="./references#CD010324-fig-0007" title="">Analysis 1.1</a>; <a href="./references#CD010324-fig-0008" title="">Analysis 1.2</a>, <a href="./references#CD010324-fig-0009" title="">Analysis 1.3</a>). </p> </section> <section id="CD010324-sec-0077"> <p><b>b. Platelet count</b></p> <p>After a nine‐month study, there was no significant difference in PLT between participants treated with either imiglucerase 60 units/kg or alglucerase 60 units/kg every two weeks (<a href="./references#CD010324-fig-0010" title="">Analysis 1.4</a>; <a href="#CD010324-fig-0004">Figure 4</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>). In the nine‐month results from the comparison study of imiglucerase and velaglucerase alfa at 60 units/kg every two weeks, there was no significant difference in PLT response when all trial participants are included in the analysis (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>). However, when participants with a history of splenectomy, in whom pre‐treatment platelet counts are most often in the high normal range (<a href="./references#CD010324-bbs2-0024" title="CharrowJ , AnderssonHC , KaplanP , KolodnyEH , MistryP , PastoresG , et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine2000;160(18):2835‐43. [PUBMED: 11025794] ">Charrow 2000)</a>, are excluded from the analysis (20 of 34 enrolled participants; 10 participants from each treatment group), a significant difference was seen, in favour of imiglucerase, MD ‐79.87 (95% CI ‐137.57 to ‐22.17) (<a href="./references#CD010324-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>). The study authors suggest that this difference may be attributable to a greater prevalence of splenic structural lesions in the velaglucerase treatment arm, a phenomenon that was not controlled in the trial and that is reported to independently affect the platelet response to ERT (<a href="./references#CD010324-bbs2-0075" title="SteinP , MalhotraA , HaimsA , PastoresGM , MistryPK . Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage‐targeted enzyme replacement therapy. Journal of Inherited Metabolic Disease2010;33(6):769‐74. [PUBMED: 20683668] ">Stein 2010</a>). On comparing taliglucerase alfa at 30 units/kg to at 60 units/kg regimen (both approximately every two weeks), at nine months, there was no statistically significant difference in PLT responses (<a href="./references#CD010324-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). </p> <div class="figure" id="CD010324-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.4 Platelets (9 months)." data-id="CD010324-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.4 Platelets (9 months). </p> </div> </div> </div> <p>In a 12‐month assessment of PLT response to either velaglucerase alfa at 45 units/kg or 60 units/kg every two weeks, no difference was seen between the different doses. This finding remained when the two participants without GD were excluded (<a href="./references#CD010324-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). </p> <p>In the de Fost and Kishnani (end‐point values analysis) imiglucerase maintenance studies, no significant differences were seen between PLT response to imiglucerase infusions at intervals of either two or four weeks, at the same monthly total dose, either at nine, 12 and up to 24 months (<a href="./references#CD010324-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD010324-fig-0011" title="">Analysis 1.5</a>, <a href="./references#CD010324-fig-0012" title="">Analysis 1.6</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). </p> </section> </section> <section id="CD010324-sec-0078"> <h6 class="title">3. Hepatosplenomegaly</h6> <section id="CD010324-sec-0079"> <p><b>a. Liver volume</b></p> <p>Six studies (234 participants) evaluated the effects of ERT on the change in liver volume. Four of these studies assessed the change in liver volume at up to nine months, and are included in the six to nine months time interval (104 participants) (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). Two studies evaluated the change at 12 months (31 participants) (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>), and one study at 24 months (89 participants) (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). No clear difference in liver volume response was seen among ERT preparations in treatment‐naïve participants nor was there any advantage. As with the determination of Hb concentration levels, no clear benefit for higher doses of velaglucerase alfa was observed even when the analysis was restricted only to participants with verified GD (<a href="./references#CD010324-fig-0013" title="">Analysis 1.7</a>; <a href="#CD010324-fig-0005">Figure 5</a>; <a href="./references#CD010324-fig-0014" title="">Analysis 1.8</a>). In the study that evaluated changes in liver volume after 24 months of treatment in stabilized participants, no significant difference was seen between imiglucerase infusions every two weeks to every four weeks (<a href="./references#CD010324-fig-0015" title="">Analysis 1.9</a>). </p> <div class="figure" id="CD010324-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.7 Liver volume (6‐9 months)." data-id="CD010324-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.7 Liver volume (6‐9 months). </p> </div> </div> </div> </section> <section id="CD010324-sec-0080"> <p><b>b. Spleen volume</b></p> <p>Four studies (82 participants) evaluated the change in spleen volume under ERT infusions in the time interval of six to nine months (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>).This was also assessed at 12 months (51 participants) (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>), and at 24 months of treatment (64 participants) (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). </p> <p>In treatment‐naïve participants, when comparing imiglucerase with alglucerase, or with velaglucerase alfa, no significant difference was seen in spleen volume changes, assessed after nine months of treatment (<a href="./references#CD010324-fig-0016" title="">Analysis 1.10</a>). Of note, this result appears to be discrepant between the effects on platelet counts, suggesting a direct impact on platelet formation and survival, rather than simply spleen function. There was no significant difference in effect of ERT dose on spleen volume response in the study in which participants were treated for nine months with taliglucerase 30 units/kg/every two weeks or 60 units/kg/every two weeks (<a href="./references#CD010324-fig-0016" title="">Analysis 1.10</a>; <a href="#CD010324-fig-0006">Figure 6</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). After 12 months of treatment, no significant difference in spleen volume was noted when comparing velaglucerase at 45 units/kg/every two weeks or at 60 units/kg/every two weeks (<a href="./references#CD010324-fig-0017" title="">Analysis 1.11</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). In the 12‐month maintenance study, different frequencies of imiglucerase administration did not show a difference favouring one treatment arm over the other (<a href="./references#CD010324-fig-0017" title="">Analysis 1.11</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>). Even at 24 months, no significant change in spleen volume was noted between different imiglucerase administration frequencies for stabilized participants (<a href="./references#CD010324-fig-0018" title="">Analysis 1.12</a>). </p> <div class="figure" id="CD010324-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.10 Spleen volume (6‐9 months)." data-id="CD010324-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.10 Spleen volume (6‐9 months). </p> </div> </div> </div> </section> </section> </section> <section id="CD010324-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD010324-sec-0082"> <h6 class="title">1. Biomarkers (chitotriosidase, CCL 18‐PARC and ACE)</h6> <p>Three studies (60 participants) evaluated the change in chitotriosidase at a six to nine months time interval (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). The de Fost study included data both for six and nine months. Only two studies evaluated the change in chitotriosidase levels at 12 months (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>), giving a total of 30 participants. Change in CCL18‐PARC levels were evaluated at nine months in two studies (63 participants) (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>), and at 12 months in one study (24 participants) (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). After nine months, there was no significant difference in the reduction of serum chitotriosidase or CCL18‐PARC in ERT‐naïve participants treated either with velaglucerase alfa or imiglucerase at 60 units/kg/every two weeks (<a href="./references#CD010324-bbs2-0001" title="Ben TurkiaH , GonzalezDE , BartonNW , ZimranA , KabraM , LukinaEA , et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. American Journal of Hematology2013;88(3):179‐84. [PUBMED: 23400823] Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , KisinovskyI , et al. Two‐year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT‐GCB‐039 and extension [abstract]. Blood2011;118(21):Poster: 3214. [CENTRAL: 977632; CRS: 5500125000000576] Ben TurkiaH , GonzalezDE , ZimranA , KabraM , LukinaEA , GiraldoP , et al. Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT‐GCB‐039 and extension [abstract]. Journal of Inherited Metabolic Disease2011;34 Suppl 3:S224, Abstract no: P‐432. [CENTRAL: 977631; CRS: 5500125000000575] ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Ben Turkia 2013</a>). There was also no significant dose effect for either dose of taliglucerase (<a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>) on reduction of chitotriosidase activity after nine months of treatment (<a href="./references#CD010324-fig-0019" title="">Analysis 1.13</a>; <a href="./references#CD010324-fig-0021" title="">Analysis 1.15</a>). However, after 12 months of treatment, confirmed GD participants receiving 60 units/kg of velaglucerase every two weeks had a greater per cent reduction (from baseline) in plasma chitotriosidase activity and in CCL 18‐PARC when compared with the 45 units/kg dose group, MD 22.61 (95% CI 7.65 to 37.57) and MD 16.70 (95% CI 1.51 to 31.89), respectively (<a href="./references#CD010324-fig-0020" title="">Analysis 1.14</a>; <a href="./references#CD010324-fig-0022" title="">Analysis 1.16</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). Chitotriosidase and CCL 18‐PARC results were not reported in the alglucerase versus imiglucerase study because these tests were not available in 1995. However, there were no differences between the treatment arms for other serum biomarkers (acid phosphatase and angiotension converting enzyme (<a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>). In the de Fost maintenance trial, there were no significant differences in chitotriosidase activity after 12 months between participants treated with imiglucerase at two‐week or four‐week intervals (<a href="./references#CD010324-fig-0020" title="">Analysis 1.14</a>). </p> <p>The change in ACE levels was assessed in two studies (40 pre‐treated participants) (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0005" title="GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine1995;122(1):33‐9. [PUBMED: 7985893] GrabowskiGA , BartonNW , PastoresG , DambrosiaJM , BanerjeeTK , McKeeMA , et al. Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose‐terminated glucocerebrosidase from natural and recombinant sources [abstract]. Blood1994, issue Suppl:226a. ">Grabowski 1995</a>). No significant differences were noted when comparing imiglucerase to alglucerase, or when comparing different frequencies of imiglucerase infusions at nine months (<a href="./references#CD010324-fig-0023" title="">Analysis 1.17</a>). Only one trial reported TRAP levels (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). The data available did not allow it to be included in the analysis. </p> </section> <section id="CD010324-sec-0083"> <h6 class="title">2. Skeletal outcomes</h6> <p>Three studies evaluated skeletal outcomes (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). In two studies, 19 participants were evaluated (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>), and in the third study, no comment was made regarding the exact number of participants evaluated (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). The wide variety of reporting for this outcome, and the lack of available numerical data, allowed limited analysis. Results are therefore described as in the original studies. </p> <p>In the de Fost study, a quantitative chemical shift imaging (QCSI) technique was used to assess lumbar bone marrow fat concentration, as an indicator of bone marrow involvement. In this technique, the difference between water and fat signal frequencies in magnetic resonance imaging allows the quantification of the fat signal fraction. If deterioration in disease severity occurs, an increase in Gaucher cell mass can lead to bone marrow involvement, which will cause a decrease in QCSI. No benefit was noted for participants treated with imiglucerase at two‐weekly intervals compared to the four‐weekly interval group, either at 6 or at 12 months (<a href="./references#CD010324-fig-0024" title="">Analysis 1.18</a>; <a href="./references#CD010324-fig-0025" title="">Analysis 1.19</a>). The study authors reported that two participants with low baseline QCSI enrolled in the low‐frequency group, were classified as treatment failures: in one of the participants a decrease from 29% at baseline to 24% QCSI at 12 months occurred, together with hepatomegaly, fatigue and abdominal discomfort, but without clinical bone problems; and in the other participant a decrease in QCSI from 33% to 23% at 12 months occurred, without any bone complications or other symptoms. A return to the high‐frequency regimen led to an increase in QCSI up to 27% at 18 months. </p> <p>Zimran reported no deterioration in bone density in any of the treatment groups (<a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). In the Gonzalez study, bone mineral density measurements were captured, but were not part of the declared objectives, and were not reported (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>). </p> </section> </section> </section> <section id="CD010324-sec-0084"> <h4 class="title">Substrate reducing therapy (SRT)</h4> <p>Two randomized controlled studies (36 GD1 and 30 GD3 participants) assessed the effect of either addition or substitution of miglustat on haemoglobin concentration, platelet count, liver and spleen volume in participants previously treated with or continuing to receive ERT (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). Elstein compared three treatment arms: miglustat; imiglucerase; and the combination of both, in pre‐treated, stabilized people with GD1 (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). Schiffmann evaluated ERT treatment compared with the combination of ERT and miglustat in people with GD3 over a period of 12 months, with an additional 12‐month extension phase where all participants received miglustat (not included in this review) (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). Additional clinical parameters, primarily related to neuronopathic manifestations, were reported in the latter study. There are no randomized GD clinical studies for miglustat or other SRT in treatment‐naïve patients that met the criteria for this analysis. </p> <section id="CD010324-sec-0085"> <h5 class="title">Primary outcomes</h5> <section id="CD010324-sec-0086"> <h6 class="title">1. Frequency of side effects</h6> <p>Elstein reported no severe adverse events during the initial six month randomization phase (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). However, 94% of participants had gastrointestinal adverse events (diarrhoea, abdominal pain, constipation, flatulence, nausea and vomiting), 68% experienced weight decrease. Information as to how many gastrointestinal adverse events were confined to participants treated with miglustat is not included in the study report. However, these adverse events are consistent with other reports of miglustat gastrointestinal side effects attributable to off‐target inhibition of intestinal disaccharidases (<a href="./references#CD010324-bbs2-0015" title="AmiriM , NaimHY . Miglustat‐induced intestinal carbohydrate malabsorption is due to the inhibition of alpha‐glucosidases, but not beta‐galactosidases. Journal of Inherited Metabolic Disease2012;35(6):949‐54. [PUBMED: 22976762] ">Amiri 2012</a>). A total of 62% of participants had neurological adverse events (tremor, dizziness, headache, fatigue, weakness). Electromyography abnormalities were noted in 8 of 36 enrolled participants (with no baseline measurements available), but all participants were asymptomatic. Two of the eight affected participants did not receive miglustat. </p> <p>The most frequent miglustat‐associated adverse events reported by participants with GD3 enrolled in the Schiffmann study were of gastrointestinal origin ‐ diarrhoea (21 participants), abdominal pain (10 participants), vomiting (six participants) and weight loss (seven participants, up to 20% decrease) (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). Ten participants needed at least one medication for these events during the initial 13 weeks of intervention, with a decrease of those needing such medications over time. Also reported were neurological adverse events, including tremor (11 participants), convulsions (six participants), headache (six participants) and "clinical or subclinical neuropathy" in four participants with previously normal EMG recordings. Of these, three were randomized to the initial 12 months miglustat intervention and one withdrew from the study. Other adverse events included cough, pyrexia, nasopharyngitis, and an increase in serum AST and prolongation of aPTT. </p> </section> <section id="CD010324-sec-0087"> <h6 class="title">2. Haemoglobin (Hb) concentrations and platelet counts (PLT)</h6> <p>In both studies, the available data did not allow the calculation of the mean effect change or the corresponding SDs for the haematological outcomes. Consequently, results are reported as in the original articles. In the Elstein study, Hb in clinically stable GD1 participants did not change significantly from baseline over a six‐month treatment period in the miglustat group (P = 1.01), the imiglucerase continuation group (P = 0.198), or in the miglustat‐imiglucerase group (P = 0.815) and no significant inter‐group differences occurred (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). Similarly, for PLT, no significant per cent changes from baseline were noted in any of the treatment arms. However, there was a statistically significant difference (20%, P = 0.035) between the imiglucerase and the miglustat arms with PLT increasing in the imiglucerase‐maintained participants and decreasing in those treated solely with miglustat. </p> <p>Type 3 GD participants randomized to receive miglustat experienced a negligible change of Hb from a baseline of 12.7 g/dL (range: 10.6 to 14.9) to 12.9 g/dL (range: 11.5 to 14.5) after 12 months of treatment (n = 18). Platelet counts at baseline were 243 x 10<sup>3</sup>/µL (range: 124 to 334) and after 12 months of intervention 241 x 10<sup>3</sup>/µL (range: 140 to 384). In participants continued solely on imiglucerase , baseline Hb was 12.3 g/dL (range: 10.7 to 14.0) and 12.7g/dL (range: 11.1 to 13.8) after 12 months. Baseline PLT was 244 x 10<sup>3</sup>/µL (range: 160 to 343) and 242 x 10<sup>3</sup>/µL (range: 134 to 348) at the end point (n = 9). No P values were reported in the original manuscript for these comparisons (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). </p> </section> <section id="CD010324-sec-0088"> <h6 class="title">3. Hepatosplenomegaly</h6> <p>Schiffmann evaluated the change in liver and spleen volumes after 12 months (no sufficient data available to be included in the analysis) (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). Elstein examined the change in liver (30 participants) and spleen volumes (22 participants) at six months (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). In the Elstein study, there was no significant difference on liver and spleen volume status between participants continued on imiglucerase and those in whom miglustat was substituted (<a href="./references#CD010324-fig-0026" title="">Analysis 2.1</a>; <a href="./references#CD010324-fig-0027" title="">Analysis 2.2</a>). Participants treated with a combination of imiglucerase and miglustat had a borderline significant decrease in liver volume compared to those maintained on imiglucerase alone, MD ‐8.75 (95% CI ‐15.63 to ‐1.87) (P = 0.047) (<a href="./references#CD010324-fig-0026" title="">Analysis 2.1</a>; <a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). A similar difference was not observed for spleen volume suggesting that, given the relative imprecision of quantitative spleen‐liver volumetric measurements, this might be a random observation (<a href="./references#CD010324-fig-0027" title="">Analysis 2.2</a>). </p> <p>In the Schiffmann study (GD3 participants), liver and spleen volumes remained essentially stable in both treatment groups at all time points (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). Participants treated with continued imiglucerase for 12 months experienced a decrease in liver volume of 0.5 L/cm<sup>3</sup>, and no change in spleen volume, while the combination of imiglucerase and miglustat resulted in decreases in liver and spleen volumes of 0.3 L/cm<sup>3</sup> and 0.2 L/cm<sup>3</sup>, respectively. </p> </section> </section> <section id="CD010324-sec-0089"> <h5 class="title">Secondary outcomes</h5> <section id="CD010324-sec-0090"> <h6 class="title">1. Biomarkers (chitotriosidase, CCL 18‐PARC and ACE)</h6> <p>The available data on biomarkers did not allow calculation of mean effect change and corresponding SDs. Results are hence reported as in the original papers. In the Schiffmann study, a decrease in chitotriosidase activity from baseline was observed in the miglustat group already at six months, while in the no miglustat group it remained unchanged up to 12 months (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). Elstein reported that all participants in each of the three treatment arms remained with stable chitotriosidase levels, although two participants experienced an increase in chitotriosidase with concurrent bone pain, which were resolved once treatment had been halted, and in one of the cases treatment with miglustat has been reinitiated afterwards (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). </p> </section> <section id="CD010324-sec-0091"> <h6 class="title">2. Skeletal outcomes</h6> <p>Elstein stated that two participants who suffered from bone pain events, which disappeared once miglustat treatment was withdrawn (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>). In one of the cases, treatment was later reinitiated. Schiffmann stated that although no cases of bone crisis events were reported during the study, one participant in the miglustat group experienced a tibial fracture after 15 months, and another participant who had history of fractures prior to enrolment in the ERT‐alone group, had two events of severe femoral fractures at 9 and 12 months (<a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010324-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010324-sec-0092"></div> <p>This systematic review summarizes, for the first time, all currently available randomized interventional studies assessing the effects of enzyme replacement and substrate reducing therapies in treating people with Gaucher disease (GD). The analysis allows for direct comparisons of the emerging new drugs with previously established treatment options for GD and focuses attention on some of the requirements for future research in this ultra‐orphan disorder. We also contend that the review provides an example for the strengths and limitations of the increasingly accepted methodology of evidence‐based medicine, specifically as reflected through the unusually distorted prism of rare diseases. </p> <p>Several principal limitations in the conduct of this review warrant consideration. As in the case of other very rare diseases, the number of studies meeting the inclusion criteria following Cochrane methodology, and the low number of participants in each of these studies, significantly limits our ability to draw rigid conclusions. An extensive search and consultation between the authors was undertaken with every effort made to ensure that all relevant data were indeed included, and to avoid oversights or over‐interpretation of any available data, and their credibility. </p> <p>Until the early 1990s, when enzyme replacement therapy (ERT) was introduced as the first specific therapy, only symptomatic drugs were available for the treatment of GD. With the support of large‐scale observational studies (<a href="./references#CD010324-bbs2-0016" title="AnderssonH , KaplanP , KacenaK , YeeJ . Eight‐year clinical outcomes of long‐term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics2008;122(6):1182‐90. [PUBMED: 19047232] ">Andersson 2008</a>; <a href="./references#CD010324-bbs2-0077" title="WeinrebNJ , CharrowJ , AnderssonHC , KaplanP , KolodnyEH , MistryP , et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine2002;113(2):112‐9. [PUBMED: 12133749] ">Weinreb 2002</a>) and the efforts of the International Collaborative Gaucher Group (ICGG), which established a GD registry in 1991, it was clear that enzyme infusions markedly improve the visceral and haematological manifestations of GD, with salutary changes often seen after only a few infusions. This improvement is also reflected in patients' reported quality of life, when compared with patients suffering from other chronic metabolic diseases (<a href="./references#CD010324-bbs2-0032" title="DamianoAM , PastoresGM , WareJEJr . The health‐related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation1998;7(5):373‐86. [PUBMED: 9691718] ">Damiano 1998</a>). The clear impact reported in the first patients receiving ERT was so remarkable (<a href="./references#CD010324-bbs2-0017" title="BartonNW , BradyRO , DambrosiaJM , DiBisceglieAM , DoppeltSH , HillSC , et al. Replacement therapy for inherited enzyme deficiency‐‐macrophage‐targeted glucocerebrosidase for Gaucher's disease. New England Journal of Medicine1991;324(21):1464‐70. [PUBMED: 2023606] ">Barton 1991</a>), that no randomized controlled studies investigating the absolute effects compared with placebo were carried out. However, with such an individual history of discovery, the ability to quantify the absolute effect of ERT and to describe the actual difference between treated and untreated individuals in a solid experimental fashion is diminished. Moreover, with the emergence of new enzyme preparations, experimental studies investigating their efficacy could only compare the new drugs with the acceptable gold standard (i.e. imiglucerase), since a randomized placebo‐controlled study would no longer have been an ethical proposition. Cognizant of these issues, it is clear that this systematic review cannot focus on the relative efficacy of given treatments, but rather, on the comparison of different treatment options, attempting to address pressing questions (such as what is the optimal dosing). It is also prudent to review all the data in a systematic manner, after which, there may be a case for investigating established evidence‐based statistical methodologies. </p> <p>For GD, which current unmet needs might constitute a worthy impetus for the development of new treatments? Unlike infectious and neoplastic diseases, refractoriness or resistance to imiglucerase is largely inconsequential, since neutralizing antibodies or intractable hypersensitivity reactions rarely occur (<a href="./references#CD010324-bbs2-0074" title="StarzykK , RichardsS , YeeJ , SmithSE , KingmaW . The long‐term international safety experience of imiglucerase therapy for Gaucher disease. Molecular Genetics and Metabolism2007;90(2):157‐63. [PUBMED: 17079176] ">Starzyk 2007</a>). The intravenous route of administration is problematical for some individuals with poor venous access including small children in whom prolonged use of infusaports or indwelling catheters might be disadvantageous. Nevertheless, market research indicates that globally, 80% to 90% of prescribed ERT infusions are actually received (<a href="./references#CD010324-bbs2-0038" title="Genzyme/Sanofi . Prescribed ERT infusions [personal communication]. Email to: Neal Weinreb2013. ">Genzyme/Sanofi 2013 [pers comm]</a>). The increasing global use of home infusion undoubtedly has contributed to increased compliance as well as accessibility (<a href="./references#CD010324-bbs2-0050" title="HughesDA , MlilliganA , MehtaA . Home therapy for lysosomal storage disorders. British Journal of Nursing2007;16(22):1386‐9. ">Hughes 2007</a>). The astronomical expense of ERT continues to be an obstacle to access even in affluent countries and much more so in under‐developed countries where large numbers of severely affected people with GD remain untreated, despite industry programs such as Project Hope and efforts of advocacy organizations such as the European Gaucher Alliance and the US National Gaucher Foundation. Although newer competitive treatments such as miglustat, velaglucerase alfa and taliglucerase alfa have been introduced at somewhat less expensive prices than imiglucerase, treatment is still unaffordable for many individuals and societies. People with GD1 have an increased risk of developing concurrent malignancies, especially multiple myeloma, other hematological malignancies, and liver and kidney carcinomas (<a href="./references#CD010324-bbs2-0072" title="RosenbloomBE , WeinrebNJ . Gaucher disease: a comprehensive review. Critical Reviews in Oncogenesis2013;18(3):163‐75. [PUBMED: 23510062] ">Rosenbloom 2013</a>). The effect of imiglucerase treatment on this risk is currently unknown. Although substantially ameliorated by imiglucerase treatment, people with GD1, especially those with a history of splenectomy, continue to develop new episodes of skeletal avascular necrosis (<a href="./references#CD010324-bbs2-0063" title="MistryPK , DeeganP , VellodiA , ColeJA , YehM , WeinrebNJ . Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. British Journal of Haematology2009;147(4):561‐70. [PUBMED: 19732054] ">Mistry 2009</a>) and GD‐associated osteopenia or osteoporosis with increased fracture risk may respond incompletely to imiglucerase ERT, especially when treatment initiation is delayed until adulthood (<a href="./references#CD010324-bbs2-0064" title="MistryPK , WeinrebNJ , KaplanP , ColeJA , GwosdowAR , HangartnerT . Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells, Molecules &amp; Diseases2011;46(1):66‐72. [PUBMED: 21112800] ">Mistry 2011</a>; <a href="./references#CD010324-bbs2-0054" title="KhanA , HangartnerT , WeinrebNJ , TaylorJS , MistryPK . Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research2012;27(8):1839‐48. [PUBMED: 22692814] ">Khan 2012</a>). Since imiglucerase is a large molecule, it is excluded from the central nervous system by the blood brain barrier and ineffective for treating classical neuronopathic GD (GD2, GD3 and intermediate phenotypes). Moreover, there is, as yet, no evidence that imiglucerase prevents the development of parkinsonism and peripheral neuropathy which are now recognized as important and sometimes life‐limiting outcomes in some middle aged and elderly people with GD1 (<a href="./references#CD010324-bbs2-0020" title="BiegstraatenM , MengelE , MarodiL , PetakovM , NiederauC , GiraldoP , et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2‐year prospective observational study. Brain: a Journal of Neurology2010;133(10):2909‐19. [PUBMED: 20693542] ">Biegstraaten 2010</a>; <a href="./references#CD010324-bbs2-0023" title="BultronG , KacenaK , PearsonD , BoxerM , YangR , SatheS , et al. The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease2010;33(2):167‐73. [PUBMED: 20177787] ">Bultron 2010</a>; <a href="./references#CD010324-bbs2-0026" title="ChetritEB , AlcalayRN , Steiner‐BirmannsB , AltarescuG , PhillipsM , ElsteinD , et al. Phenotype in patients with Gaucher disease and Parkinson disease. Blood Cells, Molecules &amp; Diseases2013;50(3):218‐21. [PUBMED: 23265741] ">Chetrit 2013</a>; <a href="./references#CD010324-bbs2-0071" title="RosenbloomB , BalwaniM , BronsteinJM , KolodnyE , SatheS , GwosdowAR , et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells, Molecules &amp; Diseases2011;46(1):95‐102. [PUBMED: 21067946] ">Rosenbloom 2011</a>). On an even more basic level, after 20 years, we cannot yet define the long‐term effects of imiglucerase therapy on health‐related quality of life or on life expectancy. </p> <p>The short‐term randomized clinical studies of recently developed new treatments for GD that we have reviewed here, although vital for regulatory approval and commercialisation of these products and thus potentially relevant to some of the socio‐economic issues raised above, do not and will not address the biological and medical questions we have raised. With that in mind, what valid conclusions may be drawn from this review that is limited to data from randomized controlled studies? Information about the comparative efficacies of imiglucerase, velaglucerase alfa and taliglucerase alfa in treatment‐naïve participants is restricted to haemoglobin (Hb) concentration, platelet counts (PLT), spleen volume, liver volume and some serum biomarker responses during the initial 9 to 12 months of therapy. In that limited context, velaglucerase and taliglucerase do not appear to be inferior to imiglucerase. There is no evidence for superiority and the studies were insufficiently designed or powered to show such an effect. As regards dose effects, in the time frame of 9 to 12 months, there appeared to be little difference in Hb, PLT, spleen, liver and biomarker responses when individuals were treated with velaglucerase 45 or 60 units/kg every two weeks or taliglucerase 30 or 60 units/kg/every two weeks. However, these studies do not address the issue of even lower doses which are commonly used with imiglucerase in a number of European countries and Israel. Furthermore, in earlier dose studies with imiglucerase (<a href="./references#CD010324-bbs2-0033" title="deFostM , HollakCE , GroenerJE , AertsJM , MaasM , PollLW , et al. Superior effects of high‐dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2‐center retrospective analysis. Blood2006;108(3):830‐5. [PUBMED: 16527890] ">de Fost 2006</a>; <a href="./references#CD010324-bbs2-0045" title="GrabowskiGA , KacenaK , ColeJA , HollakCE , ZhangL , YeeJ , et al. Dose‐response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genetics in Medicine: Official Journal of the American College of Medical Genetics2009;11(2):92‐100. [PUBMED: 19265748] ">Grabowski 2009</a>), dose‐related differences in chitotriosidase response were not evident until at least 24 months of treatment and dose‐related differences in liver and spleen size were also not clearly evident at 12 months. The observed dose differences on Hb and PLT responses reported in the Grabowski study at 12 months, may be attributable to different study design (retrospective, propensity score matching, non‐linear mixed effects modelling) and much larger participant numbers (122 participants each for doses of 15, 30 and 60 units/kg/every two weeks) (<a href="./references#CD010324-bbs2-0045" title="GrabowskiGA , KacenaK , ColeJA , HollakCE , ZhangL , YeeJ , et al. Dose‐response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genetics in Medicine: Official Journal of the American College of Medical Genetics2009;11(2):92‐100. [PUBMED: 19265748] ">Grabowski 2009</a>). In any event, the effect of ERT dose on the long‐term clinical outcomes cited above continues to be undefined. </p> <p>As regards those who appear to have an initial response and are clinically stable after at least two years of imiglucerase treatment, the randomized controlled studies (including the Kishnani study whose results were presented as composite rather than as discrete end points (<a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>)) indicate that infusion frequency can usually be reduced from every two weeks to every four weeks without adverse hematological or organ volume consequences provided that cumulative dose is maintained constant. Additionally, equal dose switches from imiglucerase to velaglucerase (<a href="./references#CD010324-bbs2-0011" title="ZimranA , PastoresGM , Tylki‐SzymanskaA , HughesDA , ElsteinD , MardachR , et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. American Journal of Hematology2013;88(3):172‐8. [PUBMED: 23339116] ">Zimran 2013b</a>; non‐randomized so not analysed above) were tolerated for 12 months without haematological or visceral changes from baseline and without unusual adverse effects. Substitution of miglustat for imiglucerase also resulted in haematological and visceral stability for 6 to 12 months but was associated with significant gastrointestinal discomfort (<a href="./references#CD010324-bbs2-0003" title="ElsteinD , DweckA , AttiasD , Hadas‐HalpernI , ZevinS , AltarescuG , et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood2007;110(7):2296‐301. [PUBMED: 17609429] ElsteinD , HeitnerR , DweckA , AttiasD , AtarescuG , ZimranA . OGT 918 as substrate reduction therapy in type I gaucher disease [abstract]. 6th Meeting of the European Haematology Association; 2001 June 21‐24; Frankfurt, Germany.. 2001:Abstract no: 212. [CENTRAL: 593107; CRS: 5500100000003060] ">Elstein 2007</a>; <a href="./references#CD010324-bbs2-0007" title="SchiffmannR , FitzgibbonEJ , HarrisC , DeVileC , DaviesEH , AbelL , et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Annals of Neurology2008;64(5):514‐22. [PUBMED: 19067373] ">Schiffmann 2008</a>). As regards all of these short‐term 'maintenance studies', it should be noted that following a 2009 to 2011 disruption in imiglucerase supply caused by a vesivirus contamination of bioreactors at the Genzyme manufacturing facility, many patients globally had their imiglucerase treatment interrupted or reduced in dose for 6 to 18 months on average. Although some individuals noted worsening fatigue and bone pain, and serum chitotriosidase activity occasionally increased in most affected by the shortage, haematological and visceral measurements generally remained unchanged (<a href="./references#CD010324-bbs2-0035" title="DeromaL , SechiA , DardisA , MacorD , LivaG , CianaG , et al. Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients. JIMD reports2013;7:117‐22. [PUBMED: 23430505] ">Deroma 2013</a>; <a href="./references#CD010324-bbs2-0040" title="GiraldoP , IrunP , AlfonsoP , DalmauJ , Fernandez‐GalanMA , FigueredoA , et al. Evaluation of Spanish Gaucher disease patients after a 6‐month imiglucerase shortage. Blood Cells, Molecules &amp; Diseases2011;46(1):115‐8. [PUBMED: 20934891] ">Giraldo 2011</a>; <a href="./references#CD010324-bbs2-0042" title='GoldblattJ , FletcherJM , McGillJ , SzerJ , WilsonM . Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia. Blood cells, Molecules &amp; Diseases2011;46(1):107‐10. [PUBMED: 20684886] '>Goldblatt 2011</a>; <a href="./references#CD010324-bbs2-0078" title="ZimranA , AltarescuG , ElsteinD . Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells, Molecules &amp; Diseases2011;46(1):111‐4. [PUBMED: 20542712] ">Zimran 2011a</a>). Thus, in people with GD1, 'stability' over a short observation period following a change in treatment may not necessarily be attributable to the new agent. </p> <section id="CD010324-sec-0093"> <h3 class="title" id="CD010324-sec-0093">Limitations of our review</h3> <p>Although we performed an extensive literature search and consulted with study authors to ensure that all the pertinent data were included and accurately interpreted, this review is nonetheless significantly constrained. The randomized controlled studies that were eligible for inclusion in this analysis represent a tiny proportion of the total body of literature reporting therapeutic outcomes in people with GD1. Additionally, the small number of participants included in the studies we analysed, who were selected on the basis of specific eligibility criteria, may not necessarily be representative of a genotypically and phenotypically diverse GD global population. In two studies we reviewed, previously treated participants were labelled "treatment naïve" after an arbitrarily chosen 'washout' period. In fact, we do not know whether these individuals respond to new treatment in identical fashion as truly‐naïve patients. The end points selected are traditional, but insufficient, surrogates for the full spectrum of GD pathophysiology. Skeletal manifestations were not addressed and direct or even indirect (via imaging) information on tissue substrate storage and histopathology is not available. Furthermore, in the context of a chronic disease whose typical course extends for decades, trial periods of one to two years necessarily lack perspective. For these reasons, we should be very cautious in reaching conclusions about absolute or comparative effectiveness of the treatments under consideration. These limitations undoubtedly extend to other rare or ultra‐rare diseases with extended prognoses and heterogeneous phenotypes and penetrance. </p> </section> <section id="CD010324-sec-0094"> <h3 class="title" id="CD010324-sec-0094">Different drugs ‐ different impact on outcomes?</h3> <p>Taking into account the results of this systematic review, it appears that the different ERTs currently available do not, under the conditions studied, show clear differences in efficacy. Mechanistically, all ERTs help to lessen disease manifestations by replacing the deficient or defective (or both) lysosomal enzyme. Of note, however, is that the modest number of participants included in these comparisons may mean that the studies are insufficiently powered to reveal superiority of one agent over the others. </p> <p>The number of studies included in this systematic review and assessing SRT in comparison with ERT is likely to be insufficient to enable the drawing of conclusions regarding the superiority or inferiority of one over the other. Eliglustat, a promising new player in the field of SRTs, currently in phase III clinical trials, is an inhibitor of N‐acylsphingosine transferase. This enzyme catalyzes the first committed step in the biosynthesis of glycosphingolipids. Therefore, it would be of particular interest to include the current phase III international trials of eliglustat in an update of this Cochrane Review. This approach may yield general data of more universal applicability and use, since the inhibition of glycosphingolipid biosynthesis has the potential to address other several glycosphingolipid disorders. </p> <p>The studies reviewed here did not address the issue of switching people from one enzyme replacement therapy to another. However, other literature suggests that this can be done safely and without loss of disease control (<a href="./references#CD010324-bbs2-0049" title="HollakCE . An evidence‐based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evidence2012;7:15‐20. [PUBMED: 22654679] ">Hollak 2012</a>; <a href="./references#CD010324-bbs2-0011" title="ZimranA , PastoresGM , Tylki‐SzymanskaA , HughesDA , ElsteinD , MardachR , et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. American Journal of Hematology2013;88(3):172‐8. [PUBMED: 23339116] ">Zimran 2013b</a>). There is evidence from two randomised controlled studies that some people with type 1 Gaucher disease, in whom disease manifestations are controlled, may be infused with imiglucerase at four‐week rather than two‐week intervals, provided that the same cumulative imiglucerase dose is unchanged (<a href="./references#CD010324-bbs2-0002" title="deFostM , AertsJM , GroenerJE , MaasM , AkkermanEM , WiersmaMG , et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica2007;92(2):215‐21. [PUBMED: 17296571] ">de Fost 2007</a>; <a href="./references#CD010324-bbs2-0006" title="KishnaniPS , DiRoccoM , KaplanP , MehtaA , PastoresGM , SmithSE , et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Molecular Genetics and Metabolism2009;96(4):164‐70. [PUBMED: 19195916] ">Kishnani 2009</a>). Similar evidence for similar studies of velaglucerase alfa and taliglucerase is not available. Given the optimal dose for ERT generally has to be determined on an individual patient basis, it is sometimes appropriate to reduce an empiric initial dose when good disease control is achieved and sustained. Clinicians occasionally elect to accomplish this by reducing the frequency of infusions without a concomitant adjustment of enzyme replacement therapy dose. At this time, there is no evidence from randomised controlled studies for this therapeutic strategy. </p> </section> <section id="CD010324-sec-0095"> <h3 class="title" id="CD010324-sec-0095">Dose of enzyme replacement therapy</h3> <p>The doses used in the eight studies included in the qualitative analysis varied from 15 units/kg up to 60 units/kg every two weeks, with only two of the studies comparing different doses head‐to‐head (<a href="./references#CD010324-bbs2-0004" title="ElsteinD , Ben TurkiaH , GonzalezDE , KabraM , LukinaEA , GiraldoP , et al. Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U/KG every other week: 2‐year results [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S150, Abstract no: P‐410. [CENTRAL: 977634; CRS: 5500125000000578] GonzalezDE , Ben DridiMF , LukinaE , KisinovskyI , Ben TurkiaH , ElsteinD , et al. Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2010;33 Suppl 1:S139, Abstract no: 442‐P. [CENTRAL: 977630; CRS: 5500125000000574] GonzalezDE , TurkiaHB , LukinaEA , KisinovskyI , DridiMF , ElsteinD , et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study. American Journal of Hematology2013;88(3):166‐71. [PUBMED: 23386328] ZimranA , KisinovskyI , LukinaEA , ElsteinD , ZahriehD , CrombezE , et al. Efficacy of long‐term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S302, Abstract no: P‐728. [CENTRAL: 977639; CRS: 5500125000000583] ">Gonzalez 2013</a>; <a href="./references#CD010324-bbs2-0008" title="ZimranA , Brill‐AlmonE , ChertkoffR , PetakovM , Blanco‐FavelaF , MunozET , et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood2011;118(22):5767‐73. [PUBMED: 21900191] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , HeitnerR , PazA , et al. A multicenter, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Blood2012;120(21):Abstract no: 2140. [CENTRAL: 977633; CRS: 5500125000000577] ZimranA , Gonzalez‐RodriguezDE , AbrahamovA , ElsteinD , PazA , Brill‐AlmonE , et al. A multi‐center, double‐blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]. Journal of Inherited Metabolic Disease2013;36 Suppl 2:S301, Abstract no: P‐724. [CENTRAL: 977638; CRS: 5500125000000582] ZimranA , MehtaA , GiraldoP , RosenbaumH , GionaF , AmatoD , et al. Long‐term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]. Journal of Inherited Metabolic Disease2012;35 Suppl 1:S11, Abstract no: O‐032. [CENTRAL: 977635; CRS: 5500125000000579] vanDussenL , ZimranA , AkkermanEM , AertsJM , PetakovM , ElsteinD , et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood cells, Molecules &amp; Diseases2013;50(3):206‐11. [PUBMED: 23199589] ">Zimran 2011b</a>). Deduced from the integrated comparisons provided herein, a beneficial effect for higher doses was observed on both CCL18 and chitotriosidase after 12 months of treatment. Yet, no statistically significant differences were noted between lower and higher doses in all other systemic outcomes. The same pattern of lack of superiority of higher doses remained when considering the excluded non‐randomized study data that assessed different doses (15 units/kg compared with 30 units/kg compared with 45 units/kg and 60 units/kg) of velaglucerase alfa (<a href="./references#CD010324-bbs2-0011" title="ZimranA , PastoresGM , Tylki‐SzymanskaA , HughesDA , ElsteinD , MardachR , et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. American Journal of Hematology2013;88(3):172‐8. [PUBMED: 23339116] ">Zimran 2013b</a>) (data not shown). However, several other studies have addressed long‐lasting questions about different effects of dosing, including a retrospective analysis of two cohorts from the Netherlands and Germany (<a href="./references#CD010324-bbs2-0033" title="deFostM , HollakCE , GroenerJE , AertsJM , MaasM , PollLW , et al. Superior effects of high‐dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2‐center retrospective analysis. Blood2006;108(3):830‐5. [PUBMED: 16527890] ">de Fost 2006</a>) and a study from the ICGG (<a href="./references#CD010324-bbs2-0045" title="GrabowskiGA , KacenaK , ColeJA , HollakCE , ZhangL , YeeJ , et al. Dose‐response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genetics in Medicine: Official Journal of the American College of Medical Genetics2009;11(2):92‐100. [PUBMED: 19265748] ">Grabowski 2009</a>). Both studies showed more robust effects of higher doses on biomarkers (<a href="./references#CD010324-bbs2-0033" title="deFostM , HollakCE , GroenerJE , AertsJM , MaasM , PollLW , et al. Superior effects of high‐dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2‐center retrospective analysis. Blood2006;108(3):830‐5. [PUBMED: 16527890] ">de Fost 2006</a>) and haematological and visceral parameters (<a href="./references#CD010324-bbs2-0045" title="GrabowskiGA , KacenaK , ColeJA , HollakCE , ZhangL , YeeJ , et al. Dose‐response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genetics in Medicine: Official Journal of the American College of Medical Genetics2009;11(2):92‐100. [PUBMED: 19265748] ">Grabowski 2009</a>). The clinical relevance of these effects are, however, not always clear. In addition, several cohorts followed the consequences of the restriction of imiglucerase distribution, which emerged after a viral contamination in the manufacturing site. In a Spanish cohort described by Giraldo (<a href="./references#CD010324-bbs2-0040" title="GiraldoP , IrunP , AlfonsoP , DalmauJ , Fernandez‐GalanMA , FigueredoA , et al. Evaluation of Spanish Gaucher disease patients after a 6‐month imiglucerase shortage. Blood Cells, Molecules &amp; Diseases2011;46(1):115‐8. [PUBMED: 20934891] ">Giraldo 2011</a>), a reduction of 50% in dosage to a mean dose of 34 units/kg for a six months period, did not result in a statistically significant decrease in haemoglobin, platelet count, or CCL18‐PARC activity ‐ but a significant increase in chitotriosidase activity was noted. Seven bone pain events in the group of 17 participants who underwent a dose reduction were also described in this cohort. Similar results were described in a 12‐month Italian cohort (<a href="./references#CD010324-bbs2-0035" title="DeromaL , SechiA , DardisA , MacorD , LivaG , CianaG , et al. Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients. JIMD reports2013;7:117‐22. [PUBMED: 23430505] ">Deroma 2013</a>), in which the dose of ERT decreased from a median of 55.5 units/kg to 15.8 units/kg, without bone pain events. </p> </section> <section id="CD010324-sec-0096"> <h3 class="title" id="CD010324-sec-0096">Role of evidence‐based analyses in rare diseases</h3> <p>Deriving evidence of value, based on medicine in the field of rare diseases, is beset with numerous obstacles ‐ the low numbers of patients and their different geographical locations set a particular challenge for the conduct of interventional trials. This is particularly true when moving from a ground‐breaking discovery which has revolutionized therapy for such a disease (as in this case with enzyme replacement for GD) to more delicate questions aimed at optimising therapeutic interventions. Inherently, differences between more subtle protocols or specific preparations are likely to be far less robust than when a new therapeutic agent that directly targets the mechanism of disease is first introduced. These considerations inevitably mandate the need for larger numbers, in order to achieve a sufficient statistical power to reveal differences or associations with confidence. </p> <p>Moving from single studies to a meta‐analysis, the high heterogeneity of such studies, often attributable to their complexity, may not allow pooled estimations, thus preventing us from fully appreciating the effects of interventions. For example, a clear distinction should be made between studies on naïve and those on pre‐treated individuals. In fact, any treatment modifies the natural course of the disease, thus different results would be predicted in untreated individuals when compared with those who receive long‐standing therapy (even if a washout period is considered). Moreover, it should be kept in mind that stable patients are less prone to experience major clinical deteriorations. Hence, when participants are stabilized before entering a study investigating a treatment switch, an underestimation of the effect of the new drug could take place. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010324-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010324-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010324-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.1 Haemoglobin levels (9 months)." data-id="CD010324-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.1 Haemoglobin levels (9 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.4 Platelets (9 months)." data-id="CD010324-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.4 Platelets (9 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.7 Liver volume (6‐9 months)." data-id="CD010324-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.7 Liver volume (6‐9 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.10 Spleen volume (6‐9 months)." data-id="CD010324-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enzyme replacement therapy, outcome: 1.10 Spleen volume (6‐9 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/full#CD010324-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 1 Haemoglobin levels (9 months)." data-id="CD010324-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 1 Haemoglobin levels (9 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 2 Haemoglobin levels (12 months)." data-id="CD010324-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 2 Haemoglobin levels (12 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 3 Haemoglobin levels (24 months) (end point values)." data-id="CD010324-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 3 Haemoglobin levels (24 months) (end point values). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 4 Platelets (9 months)." data-id="CD010324-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 4 Platelets (9 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 5 Platelets (12 months)." data-id="CD010324-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 5 Platelets (12 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 6 Platelets ‐ 24 months (end point values)." data-id="CD010324-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 6 Platelets ‐ 24 months (end point values). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 7 Liver volume (6‐9 months)." data-id="CD010324-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 7 Liver volume (6‐9 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 8 Liver volume (12 months)." data-id="CD010324-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 8 Liver volume (12 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 9 Liver volume (24 months) (multiples of normal, end point values)." data-id="CD010324-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 9 Liver volume (24 months) (multiples of normal, end point values). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 10 Spleen volume (6‐9 months)." data-id="CD010324-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 10 Spleen volume (6‐9 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 11 Spleen volume (12 months)." data-id="CD010324-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 11 Spleen volume (12 months).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 12 Spleen volume (24 months) (multiples of normal, end point values)." data-id="CD010324-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 12 Spleen volume (24 months) (multiples of normal, end point values). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 13 Chitotriosidase (6‐9 months) (% change from baseline)." data-id="CD010324-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 13 Chitotriosidase (6‐9 months) (% change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 14 Chitotriosidase (12 months) (% change from baseline)." data-id="CD010324-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 14 Chitotriosidase (12 months) (% change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 15 CCL18‐PARC (9 months) (% change from baseline)." data-id="CD010324-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 15 CCL18‐PARC (9 months) (% change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 16 CCL18‐PARC (12 months) (% change from baseline)." data-id="CD010324-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 16 CCL18‐PARC (12 months) (% change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 17 ACE (9 months) (% change from baseline)." data-id="CD010324-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 17 ACE (9 months) (% change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 18 Quantiative Chemical Shift Imaging (6 months)." data-id="CD010324-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 18 Quantiative Chemical Shift Imaging (6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enzyme replacement therapy, Outcome 19 Quantiative Chemical Shift Imaging (12 months)." data-id="CD010324-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Enzyme replacement therapy, Outcome 19 Quantiative Chemical Shift Imaging (12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Substrate reduction therapy, Outcome 1 Liver volume (6 months) (pre‐treated patients)." data-id="CD010324-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Substrate reduction therapy, Outcome 1 Liver volume (6 months) (pre‐treated patients). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010324-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/urn:x-wiley:14651858:media:CD010324:CD010324-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_t/tCD010324-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Substrate reduction therapy, Outcome 2 Spleen volume (6 months) (pre‐treated patients)." data-id="CD010324-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Substrate reduction therapy, Outcome 2 Spleen volume (6 months) (pre‐treated patients). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/media/CDSR/CD010324/image_n/nCD010324-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD010324-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Enzyme replacement therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin levels (9 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Imiglucerase 60 U/kg every 2 weeks (A) vs alglucerase 60 U/kg 2 weeks (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Taliglucerase 30 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B): participants with spleen intact only </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin levels (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Velaglucerase 45 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Velaglucerase 45 U/kg (A) vs 60 U/kg (B): verified Gaucher patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Haemoglobin levels (24 months) (end point values) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Imiglucerase every 2 weeks (A) Vs. every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Platelets (9 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Imiglucerase 60 U/kg every 2 weeks (A) vs alglucerase 60 U/kg every 2 weeks (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Taliglucerase 30 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B): patients with spleen intact only </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Platelets (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Velaglucerase 45 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Velaglucerase 45 U/kg (A) vs 60 U/kg (B): verified Gaucher patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Platelets ‐ 24 months (end point values) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Imiglucerase every 2 weeks (A) Vs. every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Liver volume (6‐9 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Imiglucerase 60 U/kg every 2 weeks (A) vs alglucerase 60 U/kg every 2 weeks (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Taliglucerase 30 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Liver volume (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Velaglucerase 45U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Velaglucerase 45 U/kg (A) vs 60 U/kg (B): Sub‐analysis: verified Gaucher patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Liver volume (24 months) (multiples of normal, end point values) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Spleen volume (6‐9 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Imiglucerase 60 U/kg every 2 weeks (A) vs alglucerase 60 U/kg every 4 weeks (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Taliglucerase 30 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Imiglucerase every 2 weeks (A) vs every 4 weeks (B (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Spleen volume (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Velaglucerase 45u/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Velaglucerase 45 U/kg (A) vs 60 U/kg (B) sub‐analysis: verified Gaucher patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Imiglucerase every 2 weeks (A) vs every 4 weeks (B (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Spleen volume (24 months) (multiples of normal, end point values) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Imiglucerase every 2 weeks (A) Vs. every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Chitotriosidase (6‐9 months) (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Taliglucerase 30 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) pre‐treated patients expressing chitotriosidase </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Chitotriosidase (12 months) (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Velaglucerase 45 U/kg (A) vs 60 U/kg (B): verified Gaucher patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Velaglucerase 45 U/kg (A) vs 60 U/kg (B): verified Gaucher patients, expressing chitotriosidase </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Imiglucerase every 2 weeks (A) vs every 4 weeks (B): pre‐treated patients expressing chitotriosidase </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 CCL18‐PARC (9 months) (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Velaglucerase 60 U/kg every 2 weeks (A) vs imiglucerase 60 U/kg every 2 weeks (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Taliglucerase 30u/kg (A) Vs. Taliglucerase 60u/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 CCL18‐PARC (12 months) (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Velaglucerase 45 U/kg (A) vs 60 U/kg (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Velaglucerase 45 u/kg (A) vs 60 U/kg (B): verified Gaucher patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 ACE (9 months) (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Imiglucerase 60 U/kg every 2 weeks (A) vs alglucerase 60 U/kg 2 weeks (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Imiglucerase every 2 weeks (A) vs every 4 weeks (B) (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Quantiative Chemical Shift Imaging (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Imiglucerase every 2 weeks (A) vs every 4 weeks (B (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Quantiative Chemical Shift Imaging (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Imiglucerase every 2 weeks (A) vs every 4 weeks (B (pre‐treated patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Enzyme replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010324-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Substrate reduction therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Liver volume (6 months) (pre‐treated patients) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Miglustat + imiglucerase (A) vs miglustat (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Miglustat (A) vs imiglucerase (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Miglustat + Imiglucerase (A) vs imiglucerase (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Spleen volume (6 months) (pre‐treated patients) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Miglustat + imiglucerase (A) vs miglustat (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Miglustat + imiglucerase (A) vs imiglucerase (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Miglustat (A) vs imiglucerase (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Substrate reduction therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010324.pub2/references#CD010324-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010324.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010324-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010324-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010324-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010324-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010324\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010324\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010324\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010324\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010324\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010324.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010324.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010324.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010324.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010324.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725630423"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010324.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725630427"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010324.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7fef5cfcf466',t:'MTc0MDcyNTYzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 